Novel aminoalkanoic acid derivative containing biphenyl group and antifungal pharmaceutical composition comprising the same

ABSTRACT

The present invention relates to a derivative compound in which a biphenyl group is introduced into an aminoalkanoic acid, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The compound of the present invention exhibits excellent antifungal and fungicidal effects. Furthermore, the compound of the present invention exhibits a synergistic effect when used in combination with a conventional antifungal agent. Furthermore, the compound of the present invention provides broad-spectrum antifungal activity against a wide range of fungal pathogens. Therefore, the compound of the present invention may be widely used in fields requiring treatment with antifungal or fungicidal agents against human pathogenic fungi and animal pathogenic fungi, and phytopathogenic fungi.

CROSS-REFERENCE TO RELATED APPLICATION

The present application is a continuation application of InternationalApplication No. PCT/KR2020/008306 filed Jun. 25, 2020, which claimspriority to Korean Patent Application No. 10-2019-0075893 filed Jun. 25,2019. The applications are incorporated herein by reference.

TECHNICAL FIELD

The present invention relates to a derivative compound in which abiphenyl group is introduced into an aminoalkanoic acid, a stereoisomerthereof, or a pharmaceutically acceptable salt thereof, and apharmaceutical composition for preventing and/or treating a fungalinfectious disease, including the same as an active ingredient.

BACKGROUND ART

The longer the life span of the contemporary people, the moreopportunistic fungal infections increase especially among the elderlydue to the decline of immune functions. Furthermore, infections byopportunistic infectious fungi are increasing worldwide, in particularamong the immune-compromised patients who are treated withimmunosuppressive agents to reduce a transplant rejection response, orthe organ transplant patients with impaired immune functions, orpatients with weakened immunity due to chemotherapy or acquiredimmunodeficiency syndrome (AIDS). For fungal infections in the past,local fungal infections such as athlete's foot, tinea cruris and thrushcommonly occurred, but recently, systemic fungal infections have tendedto occur so frequently that they are the fourth most common of allinfection types in hospitals. As representative opportunistic pathogenicfungi, Candida albicans, Candida glabrata, Candida krusei, Cryptococcusneoformans, and the like have been reported. Cryptococcus neoformans,which is a pathogenic fungus causing systemic infections, is typicallyfound in soil worldwide, and its basidiospores could be inhaled from thesurrounding environment into the lungs through the human respiratoryorgans. In the case of patients with weakened immunity, such as organtransplant patients or patients with AIDS, fungi lurking in the lungsmay evoke lung infections and penetrate into the central nervous systemthrough the blood-brain barrier (BBB) to cause life-threateningencephalomeningitis. In particular, encephalomeningitis caused byCryptococcus results in the highest mortality rate amongencephalomeningitis, with more than 600,000 deaths worldwide each year.However, since fungi consist of eukaryotic cells like animal cells, thebiochemical metabolic pathways of fungi and mammals are so similar thatit is difficult to find fungal-specific drug target. Thus, conventionalantifungal agents to treat cryptococcosis have a number of limitationsin their clinical use. The antifungal agents developed so far tosuppress Cryptococcus fungi include polyene class comprisingamphotericin B; azole class comprising ketoconazole, fluconazole,itraconazole, and voriconazole; and non-azole class such as terbinafineand flucytosine; echinocandin class such as caspofungin. Amphotericin B,one of the polyene antifungals, binds to ergosterol in cell membrane ofCryptococcus to induce oxidative damage and causes fungal cell death.The amphotericin B, however, causes adverse effects resulting from itssevere toxicity to the human body. Azole class antifungals are known toinhibit biosynthesis of ergosterol, one of the essential elements offungal cell membrane, by inhibiting 14-α-demethylase which is involvedin the conversion of lanosterol to ergosterol, thereby weakening thecell membrane and causing fungal cell death. It was reported, however,that emergence of azole resistance within fungal species has beenincreased. Terbinafine suppresses ergosterol synthesis by inhibiting theconversion of squalene to squalene epoxy. Flucytosine, which is ametabolic antagonist inhibiting nucleic acid synthesis, exhibitsantifungal effects by causing fungal RNA miscoding and antagonizingfungal DNA synthesis. Echinocandin class antifungals reveal antifungaleffects by inhibiting fungal cell wall synthesis while the otherantifungal agents mentioned above act on fungal cell membrane. Asdisclosed above, the conventional antifungal agents or drugs have anumber of problems of side effects such as severe toxicity and drugresistance development, etc. Therefore, it has been highly required todevelop a new class antifungal agent which is capable of enhancingantifungal effects while minimizing side effects.

SUMMARY

The present invention is to provide a novel aminoalkanoic acidderivative containing a biphenyl group, a salt and/or a solvate thereof.

In addition, the present invention is to provide an antifungalpharmaceutical composition comprising the said aminoalkanoic acidderivative, a salt and/or a solvate thereof as an active ingredient.

In addition, the present invention is to provide an agriculturalantifungal agent comprising the said aminoalkanoic acid derivative, asalt and/or a solvate thereof as an active ingredient.

Furthermore, the present invention is to provide an animal antifungalagent comprising the said aminoalkanoic acid derivative, a salt and/or asolvate thereof as an active ingredient.

Furthermore, the present invention is to provide an antifungalcomposition comprising the said aminoalkanoic acid derivative, a saltand/or a solvate thereof as an active ingredient.

Furthermore, the present invention is to provide a human body cleansingcomposition, cosmetic composition, or shampoo composition comprising thesaid aminoalkanoic acid derivative, a salt and/or a solvate thereof asan active ingredient.

Furthermore, an object of the present invention is to provide a methodfor preparing a benzyloxybenzylaminyl amino acid derivative of thepresent invention.

As one aspect to achieve the objects above, the present inventionprovides a compound represented by the following Formula 1, astereoisomer thereof, or a pharmaceutically acceptable salt thereof:

in the said Formula 1,

n is 0, 1, 2, 3, 4 or 5,

R₁, R₂, and R₃ are each independently the same as or different from eachother, and are each independently selected from hydrogen, a C₁₋₇ alkyl,hydroxyl, a halogen, a halogenated C₁₋₇ alkyl, a C₁₋₇ alkyloxy and ahalogenated C₁₋₇alkyloxy, and

X is m substituents (m is an integer from 1 to 5) which are the same asor different from each other, selected from the group consisting of ahalogen group, a halogenated C₁₋₇ alkyl group and a halogenated C₁₋₇alkoxy group.

In addition, the compound represented by the Formula 1 is a compoundhaving no limitation on a 3D arrangement structure of a substituentattached to a chiral carbon, and may include all structurally availableenantiomers or optical isomers. In particular, the compound representedby the Formula 1 may be provided in the form of a (R) or (S) isomerthereof alone or a mixture thereof, for example, a racemic mixture orracemate thereof, but not limited thereto.

In the present invention, the halogen may be selected from the groupconsisting of fluoro, chloro, bromo and iodo, and

the C₁₋₇ alkyl may be a straight, branched or cyclic alkyl, and may beselected from the group consisting of methyl, ethyl, propyl, isopropyl,cyclopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, hexyl, heptyland octyl.

The C₁₋₇ alkyloxy group may be selected from the group consisting ofmethoxy, ethoxy, propoxy, butoxy, pentoxy, hexyloxy, heptyloxy andoctyloxy.

The halogenated C₁₋₇ alkyl may be selected from the group consisting ofdifluoromethyl, trifluoromethyl, difluoroethyl, trifluoroethyl,trifluoropropyl, trifluoropentyl, trifluorohexyl and trifluoroheptyl,and

the halogenated C₁₋₇ alkyloxy may be selected from the group consistingof difluoromethyloxy, trifluoromethyloxy, difluoroethyloxy,trifluoroethyloxy, trifluoropropyloxy, trifluoropentyloxy,trifluorohexyloxy and trifluoroheptyloxy.

The present invention may include not only the said Formula 1 or apharmaceutically acceptable salt thereof, but also a solvate or hydratepresenting the same effects, which can be prepared therefrom within thescope of the present invention.

The compound of the present invention is based on an aminoalkanoic acidand may be a derivative in which a biphenyl group is introduced into theaminoalkanoic acid.

For example, the aminoalkanoic acid may be an α-amino acid derivativecontaining a C₂₋₄ straight hydrocarbon chain in the side chain, forexample, α-aminobutyric acid, norvaline or norleucine.

As used herein, the term “α-aminobutyric acid (AABA)” refers to acompound represented by the following Formula 6, which has an IUPAC nameof 2-aminobutyric acid, and is a non-proteinogenic α-amino acid offormula C₄H₉NO₂, which is also known to be homoalanine in biochemistry.The α-aminobutyric acid includes a C₂ straight hydrocarbon chain in theside chain, which contains additional C₁ comparing to alanine.

As used herein, the term “norvaline (Nva)” refers to a compoundrepresented by the following Formula 7, which has an IUPAC name of2-aminopentanoic acid, and is a water-soluble amino acid that is anisomer of valine, which is a branched chain amino acid (BCAA) of formulaCH₃(CH₂)₂CH(NH₂)CO₂H.

As used herein, the term “norleucine (Nle)” refer to a compoundrepresented by the following Formula 8, which has an IUPAC name of2-aminohexanoic acid, and is an amino acid having the formulaCH₃(CH₂)₃CH(NH₂)CO₂H.

For example, the compound of the present invention may be a compound inwhich R₁ and R₂ are each independently H or methyl, ethyl, n-propyl,isopropyl, cyclopropyl, n-butyl, isobutyl, cyclobutyl, n-pentyl,cyclopentyl, n-hexyl or cyclohexyl, and R₃ is methyl, ethyl, n-propyl,isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.

Furthermore, the compound of the present invention may be a compound inwhich R₁ and R₂ are each independently H or methyl, and R₃ is methyl,ethyl, or n-propyl, but not limited thereto.

For example, X in the compound of the present invention may be any oneor two identical or different substituents selected from the groupconsisting of fluoro, chloro, trifluoromethyl and trifluoromethoxy. Forexample, the substituent may be one, or two or more which are the sameas each other or differently selected.

For example, X in the compound of the present invention may be fluoro,chloro, trifluoromethyl or trifluoromethoxy, and in particular, X may bep-fluoro, m-fluoro, p,m-difluoro, p-chloro, m-chloro, p,m-dichloro,p-trifluoromethyl or p-trifluoromethoxy, but not limited thereto.

Specifically, non-limiting examples of the compound of the presentinvention may include:

-   1) 2-amino-N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)butanamide;-   2) 2-amino-N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)pentanamide;-   3) 2-amino-N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)hexanamide;-   4)    2-amino-N-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)pentanamide;-   5)    N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(methylamino)butanamide;-   6)    N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(methylamino)pentanamide;-   7)    N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(methylamino)hexanamide;-   8)    N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(dimethylamino)pentanamide;-   9)    2-amino-N-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)pentanamide;-   10)    2-amino-N-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)hexanamide;-   11)    2-amino-N-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)pentanamide;-   12)    2-amino-N-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)hexanamide;-   13)    2-amino-N-((4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)methyl)pentanamide;-   14)    2-amino-N-((4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)methyl)hexanamide;-   15)    N-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)-2-(methylamino)pentanamide;-   16)    2-(methylamino)-N-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)pentanamide;-   17)    N-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)-2-(dimethylamino)pentanamide;-   18)    2-amino-N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)butanamide;-   19)    2-amino-N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)pentanamide;-   20)    2-amino-N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)hexanamide;-   21)    2-amino-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)butanamide;-   22)    2-amino-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)pentanamide;-   23)    2-amino-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)hexanamide;-   24)    2-amino-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)butanamide;-   25)    2-amino-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)pentanamide;-   26)    2-amino-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)hexanamide;-   27)    2-amino-N-(2-(3′,4′-difluoro-[1,1′-biphenyl]-4-yl)ethyl)pentanamide;-   28)    N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(methylamino)butanamide;-   29)    N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(methylamino)pentanamide;-   30)    N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(methylamino)hexanamide;-   31)    2-(methylamino)-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)butanamide;-   32)    2-(methylamino)-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)pentanamide;-   33)    2-(methylamino)-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)hexanamide;-   34)    2-(methylamino)-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)butanamide;-   35)    2-(methylamino)-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)pentanamide;-   36)    2-(methylamino)-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)hexanamide;    and-   37)    N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(dimethylamino)pentanamide.

The compound of the present invention may be in the form of apharmaceutically acceptable salt. As a salt, an acid addition saltformed by a pharmaceutically acceptable free acid may be used. As usedherein, the term “pharmaceutically acceptable salt” refers to an organicor inorganic addition salt of the compound represented by Formula 1 thatis tolerated and sufficiently non-toxic to be used for patients at anyconcentration exhibiting pharmacological effects of the compound.

The acid addition salt is prepared by typical methods, for example,dissolving the compound in an excess aqueous acid solution, andprecipitating the obtained salt using a water-miscible organic solvent,for example, methanol, ethanol, acetone or acetonitrile. The same molaramount of compound and acid or alcohol (for example, glycol monomethylether) in water are heated, and then the resulting mixture may beevaporated and dried, or the precipitated salt may be suction filtered.

In this case, as the free acid, organic acids and inorganic acids may beused. Further, as the inorganic acids, hydrochloric acid, phosphoricacid, sulfuric acid, nitric acid, tartaric acid, and the like may beused, and as the organic acids, methanesulfonic acid, p-toluenesulfonicacid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid,oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid,propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid,galacturonic acid, glutamic acid, glutaric acid, glucuronic acid,aspartic acid, ascorbic acid, carbonic acid, vanillic acid, hydroiodicacid, and the like may be used, but the free acid is not limitedthereto.

Further, a pharmaceutically acceptable metal salt may be prepared usinga base. An alkali metal salt or an alkaline earth metal salt isobtained, for example, by dissolving the compound in an excessive amountof an alkali metal hydroxide or alkaline earth metal hydroxide solution,filtering a non-dissolved compound salt, and then evaporating and dryinga filtrate. In this case, as the metal salt, it is pharmaceuticallypreferable to prepare particularly, sodium, potassium, or calcium salts,but the metal salt is not limited thereto. In addition, a silver saltcorresponding thereto may be obtained by reacting an alkali metal oralkaline earth metal salt with a suitable silver salt (for example,silver nitrate).

The pharmaceutically acceptable salt of the compound of the presentinvention includes a salt of an acidic or basic group that may bepresent in the compound of Formula 1, unless otherwise indicated. Forexample, the pharmaceutically acceptable salt may comprise sodium,calcium, potassium salts and the like of a hydroxyl group. The examplesof other pharmaceutically acceptable salts of an amino group includehydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate,dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate,mandelate, methanesulfonate (mesylate), p-toluenesulfonate (tosylate)salts, and the like, and may be prepared by a salt preparation methodknown in the art.

The salt of the compound of Formula 1 of the present invention is apharmaceutically acceptable salt, and any salt is available withoutlimitation as long as the salt shows a pharmacological activityequivalent to that of the compound of Formula 1. For example, a salt ofthe compound of Formula 1 presents antifungal activity.

As another aspect, the present invention provides a method for preparinga derivative compound, a stereoisomer thereof, or a pharmaceuticallyacceptable salt thereof in which a biphenyl group is introduced into theaminoalkanoic acid, the method including a first step of forming apeptide bond by reacting an aminoalkanoic acid derivative compoundprotected by a butoxycarbonyl (Boc) protecting group, which isrepresented by the following Formula 2, with a biphenyl derivativecompound including a primary amine group, which is represented by thefollowing Formula 3; and a second step of removing the Boc protectinggroup by reacting the compound obtained in the first step with an acid:

in Formula 1,

n is 0, 1, 2, 3, 4 or 5,

R₁, R₂, and R₃ are each independently the same as or different from eachother, and are each independently selected from the group consisting ofhydrogen, a C₁₋₇ alkyl, hydroxyl, a halogen, a halogenated C₁₋₇ alkyl, aC₁₋₇ alkyloxy and a halogenated C₁₋₇ alkyloxy, and

X is m substituents (m is an integer from 1 to 5) which are the same asor different from each other, selected from the group consisting of ahalogen group, a halogenated C₁₋₇ alkyl group and a halogenated C₁₋₇alkoxy group.

In the preparation method of the present invention, the aminoalkanoicacid derivative compound protected by the Boc protecting group, which isrepresented by Formula 2 may be prepared by reacting an amino acidderivative represented by the following Formula 4 with di-tert-butyldicarbonate (also known as Boc anhydride):

in the said Formula 4,

R₁′, R₂, and R₃ are each independently the same as or different fromeach other, and are each independently selected from the groupconsisting of hydrogen, a C₁₋₇ alkyl, hydroxyl, a halogen, a halogenatedC₁₋₇ alkyl, a C₁₋₇ alkyloxy and a halogenated C₁₋₇ alkyloxy.

In this case, when R₂ of the finally prepared compound is an alkyl, astep of alkylating the compound by reacting the compound with ahaloalkane in the presence of a base after the above reaction may befurther performed. For example, the alkylation may be carried out bydissolving the compound represented by Formula 4 and a haloalkanecompound corresponding 5 to 20 equivalents of the compound, for example,alkane iodide in an organic solvent, for example, tetrahydrofuran,adding sodium hydride as a base at a low temperature, for example, 0° C.and then reacting the reactants at 15 to 30° C. for 12 to 48 hours, butnot limited thereto. An alkylation reaction of amines known in the artmay be used without limitation or performed by being modified.

Meanwhile, in the preparation method of the present invention, abiphenyl derivative compound containing a primary amine group, which isrepresented by Formula 3 may be prepared by reacting a C₀₋₂ alkylaminederivative in which a halophenyl group at one end is substituted, whichis represented by the following Formula 5 with di-tert-butyl dicarbonateto introduce a Boc protecting group into an amine group, reacting theresulting alkylamine derivative with a phenylboronic acid derivativerepresented by the following Formula 6, and then reacting the reactantswith an acid to remove the Boc protecting group:

in the said formulae,

X′ is a halogen, and

X is m substituents (m is an integer from 1 to 5) which are the same asor different from each other, selected from the group consisting of ahalogen group, a halogenated C₁₋₇ alkyl group and a halogenated C₁₋₇alkoxy group.

In this case, the reaction with the phenylboronic acid derivative may beachieved by a cross-coupling reaction using a metal catalyst in thepresence of a base. For example, the reaction may be performed underbasic conditions by a metal catalyst such as palladium or nickel. Themetal catalyst may be a catalyst in which a phosphine ligand is bound toa metal. For example, the reaction may be a Suzuki-Miyauracross-coupling reaction performed by Pd(PPh₃)₄ in the presence ofNa₂CO₃, but is not limited thereto.

For example, in the preparation method of the present invention, thefirst step may be achieved by an anhydride coupling reaction performedin an organic solvent in the presence of N-methylmorpholine (NMM) orisobutyl chloroformate (IBCF). As the organic solvent, tetrahydrofuranmay be used, but the organic solvent is not limited thereto.

For example, in the preparation method of the present invention, thesecond step to remove the Boc protecting group may be performed bycarrying out a reaction with hydrochloric acid, but is not limitedthereto.

Furthermore, the preparation method of the present invention may furtherinclude a third step of forming a secondary amine by alkylating amineafter the second step when each of R₁ and R₂ of the compound finallyprepared is an alkyl. The amination may be performed by reacting withformaldehyde while supplying hydrogen gas in the presence of Pd/C as areducing agent. For example, the reaction may be performed at 15 to 30°C. for 6 to 24 hours, but is not limited thereto, and the alkylationreaction of amines known in the art may be used without limitation orperformed by being modified.

As still another aspect, the present invention provides an antifungalcomposition comprising, as an active ingredient, a derivative compoundin which a biphenyl group is introduced into an aminoalkanoic acid, anda stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

As yet another aspect, the present invention provides a pharmaceuticalcomposition for treating or preventing a fungal infectious disease,wherein the composition comprises, as an active ingredient, anaminoalkanoic acid derivative into which a biphenyl group is introduced,a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

For example, the novel aminoalkanoic acid derivative into which abiphenyl group is introduced, a stereoisomer thereof, or apharmaceutically acceptable salt thereof of the present invention mayexhibit antifungal activity against opportunistic infectious fungi, andthus may be used as an antifungal composition, and furthermore, may beused for preventing or treating a fungal infectious disease.

As used herein, the term “prevention” refers to any actions thatsuppress, inhibit or delay the onset, development or recurrence of anyconcerned disease by administering the said pharmaceutical composition.The term “treatment” refers to any actions in which the symptoms of anyconcerned disease are alleviated or beneficially improved byadministering the said pharmaceutical composition.

For example, a fungal infectious disease that can be prevented ortreated by the pharmaceutical composition of the present invention mayinclude, for example, infectious diseases caused by Cryptococcusneoformans, Candida albicans, Candida auris, Candida glabrata, andAspergillus fumigatus. The fungal infectious disease may beencephalomeningitis caused by Cryptococcus, but not limited thereto.

The pharmaceutical composition according to the present invention maycomprise, as an active ingredient, a compound represented by Formula 1,a stereoisomer thereof, or a pharmaceutically acceptable salt thereof,and may also further include a pharmaceutically acceptable carrier,diluent or excipient. For example, the pharmaceutical compositionaccording to the present invention may be formulated and used in variousforms such as an oral dosage form such as a powder, granules, a tablet,a capsule, a suspension, an emulsion, a syrup, or an aerosol, or aninjection of a sterile injection solution by a conventional methodaccording to each intended use, and may be administered orally orthrough various routes including intravenous, intraperitoneal,subcutaneous, rectal, topical administration and the like. Examples of asuitable carrier, diluent, or excipient that may be included in such acomposition include lactose, dextrose, sucrose, sorbitol, mannitol,xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin,calcium phosphate, calcium silicate, cellulose, methylcellulose,microcrystalline cellulose, polyvinylpyrrolidone, water,methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate,mineral oil, and the like. Further, the composition of the presentinvention may further include a filler, an anticoagulant, a lubricant, awetting agent, a fragrance, an emulsifying agent, a preservative, andthe like.

A solid preparation for oral administration includes a tablet, a pill, apowder, granules, a capsule, and the like, and the solid preparation isformulated by mixing at least one excipient, for example, starch,calcium carbonate, sucrose, lactose, gelatin, and the like with thecomposition. Further, in addition to a simple excipient, a lubricantsuch as magnesium stearate and talc may be used.

As a liquid preparation for oral administration, a suspension, a liquidfor internal use, an emulsion, a syrup or the like may be used, and inaddition to water and liquid paraffin, which are simple commonly useddiluents, various excipients, for example, a wetting agent, a sweetener,a flavoring agent, a preserving agent or the like may be employed.

Examples of a preparation for parenteral administration include anaqueous sterile solution, a non-aqueous solvent, a suspension, anemulsion, a freeze-dried preparation, and a suppository. As thenon-aqueous solvent and the suspension, it is possible to use propyleneglycol, polyethylene glycol, a vegetable oil such as olive oil, aninjectable ester such as ethyl oleate, and the like. As a base of thesuppository, it is possible to use Witepsol®, Macrogol, Tween 61, cacaobutter, laurin fat, glycerogelatin, and the like. Meanwhile, theinjection may include additives in the related art, such as asolubilizer, an isotonic agent, a suspending agent, an emulsifier, astabilizer, and a preservative.

The composition of the present invention is administered in apharmaceutically effective amount. The term “pharmaceutically effectiveamount” as used herein refers to an amount that is sufficient enough totreat diseases at a reasonable benefit/risk ratio applicable to medicaltreatment and does not cause side effects, and an effective dosage levelmay be determined according to various factors including patient'shealth status, type of diseases, severity of disease, activity of drugs,sensitivity to drugs, administration method, administration time,administration route and excretion rate, duration of treatment, anddrugs used in combination or simultaneously, and other factors wellknown in the medical field. The composition of the present invention maybe administered as an individual therapeutic agent or in combinationwith other therapeutic agents, may be administered sequentially orsimultaneously with certain conventional therapeutic agents, and may beadministered in a single dose or multiple doses. It is important toadminister the composition in a minimum amount that can obtain themaximum effects without any side effects, in consideration of all theaforementioned factors, and this amount may be easily determined bythose skilled in the art.

For example, since the amount may be increased or decreased depending onthe administration route, the severity of disease, gender, body weight,age, and the like, the dosage is not intended to limit the scope of thepresent invention in any way.

Furthermore, the present invention provides a method for treating afungal infectious disease, the method including administering thepharmaceutical composition to an individual in need thereof.

As used herein, the term “individual” refers to animals including amonkey, a cow, a horse, a sheep, a pig, a chicken, a turkey, a quail, acat, a dog, a mouse, a rat, a rabbit, or a guinea pig, including a humanwho developed a fungal infectious disease or is likely to develop thefungal infectious disease, and the disease may be effectively preventedor treated by administering the pharmaceutical composition of thepresent invention to an individual. Further, the pharmaceuticalcomposition of the present invention exhibits a therapeutic effect on adisease induced by a fungal infection due to the antifungal activitythereof, and thus may exhibit a synergistic effect when administered incombination with an existing therapeutic agent.

As used herein, the term “administration” refers to provision of apredetermined material to a patient by any appropriate method. Withregard to the route of administration of the composition of the presentinvention, the composition of the present invention may be administeredvia any general route, which may reach a target tissue. The route ofadministration may be intraperitoneal administration, intravenousadministration, intramuscular administration, subcutaneousadministration, intradermal administration, oral administration, topicaladministration, intranasal administration, intrapulmonaryadministration, and rectal administration, but is not limited thereto.In addition, the pharmaceutical composition of the present invention mayalso be administered by any device which may allow an active material oringredient to move to a target cell. Preferred administration modes andpreparations are intravenous injection, subcutaneous injection,intradermal injection, intramuscular injection, drip injection and thelike. An injectable preparation may be prepared using an aqueous solventsuch as physiological saline and Ringer's solution, a non-aqueoussolvent such as a vegetable oil, a higher fatty acid ester (for example,ethyl oleate, and the like), and an alcohol (for example, ethanol,benzyl alcohol, propylene glycol, glycerin, and the like), and mayinclude a pharmaceutical carrier such as a stabilizer for preventingspoilage (for example, ascorbic acid, sodium bisulfite, sodiumpyrosulfite, BHA, tocopherol, EDTA, and the like), an emulsifier, abuffer for pH control, and a preservative for inhibiting microbialgrowth (for example, phenylmercuric nitrate, thimerosal, benzalkoniumchloride, phenol, cresol, benzyl alcohol, and the like).

The term “therapeutically effective amount” used in combination with theactive ingredient in the present invention refers to an amount of aaminoalkanoic acid derivative compound in which a biphenyl group isintroduced into aminoalkanoic acid, which is effective for preventing ortreating a target disease, a stereoisomer thereof, or a pharmaceuticallyacceptable salt thereof.

According to various exemplary embodiments of the present invention, thedisadvantages of conventional drugs used as antifungal agents can beovercome through a compound using an aminoalkanoic acid containing abiphenyl group, for example, alpha-aminobutyric acid or norvaline ornorleucine as a basic skeleton. In particular, the present invention canprovide antifungal agents having improved safety and efficacy toalleviate or eliminate the side effects of the conventional antifungalsand to enhance therapeutic effects. Therefore, the present invention canprovide a pharmaceutical composition to treat and/or prevent variousfungal infectious diseases. Further, the compound of the presentinvention can be used to prepare an antibacterial composition againstgram-positive, gram-negative, and MRSA-resistant bacteria. In addition,the compound of the present invention can be used for the development ofan anti-inflammatory therapeutic agent.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 compares the antifungal activity of Compound 74 of the presentinvention with those of commercially available comparative drugs.

FIG. 2 compares the fungicidal activity of Compound 74 of the presentinvention with those of commercially available comparative drugs.

FIG. 3 compares the effect of removing a biofilm of Compound 74 of thepresent invention with those of commercially available comparativedrugs.

DETAILED DESCRIPTION

Hereinafter, the present invention will be described in more detail withreference to the following Preparation Examples and Examples. However,the following Preparation Examples and Examples are only forexemplifying the present invention, and the scope of the presentinvention is not limited thereto.

First, reactions used in the synthesis of the compound of the presentinvention were generalized and summarized as follows.

Reaction Scheme a—Introduction of Boc Protecting Group

Norleucine (1.0 eq), Boc anhydride (1.5 eq), and sodium bicarbonate (1.5eq) were dissolved in a 1:1 mixed solvent of distilled water andmethanol and reacted at room temperature for 36 to 48 hours. After themixture was concentrated in a vacuum state, the pH of an aqueous layerwas adjusted to 2 with 1.0 M hydrochloric acid. Then, the moisture of anorganic layer obtained by extraction with ethyl acetate was removed withsodium sulfate, and the solvent was evaporated in vacuum to obtain thetitle compound.

Reaction Scheme b—Methylation of Amine Group

The compound (1.0 eq) obtained from Reaction Scheme a and iodomethane(10 eq) were dissolved in a tetrahydrofuran solvent, and sodium hydride(10 eq) was very slowly added dropwise thereto at 0° C. The reactantswere reacted at room temperature for 24 hours. After the reaction wascompleted, the resulting product was diluted with an ether solvent, anddistilled water was added thereto. The pH of an aqueous layer wasadjusted to 2 with a 20% citric acid solution. Then, the moisture of anorganic layer obtained by extraction with ethyl acetate was removed withsodium sulfate, and the solvent was evaporated in vacuum. The obtainedresidue was separated and purified by chromatography using silica gel toobtain the title compound.

Reaction Scheme C—Introduction of Boc Protecting Group on Primary AmineGroup

After 4-bromophenetylamine (1.0 eq) was dissolved in a methylenechloride solvent, potassium carbonate (1.5 eq) and Boc anhydride (1.05eq) were added thereto, and the resulting mixture was reacted at roomtemperature for about 12 to 18 hours. The reaction mixture was dilutedwith methylene chloride and washed twice with distilled water. Theorganic layer was dried with sodium sulfate and then concentrated invacuum. The obtained residue was washed with hexane and then evaporatedin a vacuum state to obtain the title compound.

Reaction Scheme d—Synthesis of Biphenylamine Hydrochloride Derivative

The compound obtained from Reaction Scheme c, tert-butyl(4-bromobenzyl)carbamate or tert-butyl (4-bromophenyl)carbamate (1.0eq), benzene boronic acid (1.5 eq), sodium carbonate (5.0 eq), andtetrakis(triphenylphosphine)palladium (0.04 eq) were dissolved in a 2:1to 2.5:1 mixed solvent of degassed toluene and distilled water, andreacted under reflux at a temperature of 140° C. for 12 to 18 hours.After the reaction, the catalyst was removed by filtration throughCelite, and the solvent was evaporated from the filtered organic layerin a vacuum state. The obtained residue was separated and purified bychromatography using silica gel. After the purified product wasdissolved in an ethyl acetate solvent, the resulting solution wasstirred at room temperature while adding 4.0 M hydrochloric acid (6.0 to10.0 eq) thereto. The obtained white solid in the form of a salt waswashed with ethyl acetate, and then completely dried in a vacuum stateto obtain the title compound.

Reaction Scheme e—Mixed Anhydride Coupling (MAC) Reaction

The compound synthesized according to Reaction Scheme a or the compoundsynthesized according to Reaction Scheme b (1.0 eq), andN-methylmorpholine (NMM, 2.5 to 2.8 eq) were put into a distilledtetrahydrofuran solvent and the resulting mixture was stirred for 15minutes. Then isobutyl chloroformate (IBCF, 1.3 eq) was added thereto,and the resulting mixture was further stirred for 15 minutes, and thenthe compound (1.05 eq) obtained from Reaction Scheme d was addedthereto. The reaction mixture was allowed to react at room temperaturefor about 3 to 5 hours. The mixture was filtered to evaporate thesolvent in a vacuum state. The obtained residue was separated andpurified by chromatography using silica gel to obtain the titlecompound.

Reaction Scheme f—Removal of Boc Protecting Group

After the compound derivative (1.0 eq) obtained from Reaction Scheme ewas dissolved in an ethyl acetate solvent, the resulting solution wasstirred at room temperature while adding 4.0 M hydrochloric acid (6.0 to10.0 eq) thereto. The obtained white solid in the form of a salt waswashed with ethyl acetate, and then completely dried in a vacuum stateto obtain the title compound.

Reaction Scheme g—Dimethylation of Amine Group

The compound (1.0 eq) obtained from Reaction Scheme f was dissolved inmethanol, triethylamine (6.0 eq) was added thereto, and thenformaldehyde (37% by weight solution, 1.0 to 2.5 eq) and a 10% palladiumcatalyst (0.1 to 0.5 eq) were sequentially added thereto. The reactantswere reacted at room temperature for 18 hours. After the reaction, thecatalyst was removed by filtration through Celite, and the filteredorganic layer was evaporated in a vacuum state to obtain a white solid.The resulting product was recrystallized with methanol and diethyl etherto obtain the title compound.

Preparation Examples for synthesizing the compound of the presentinvention are as follows.

PREPARATION EXAMPLES Preparation Example 1: Preparation of(R)/(S)-2-((tert-butoxycarbonyl)amino)butanoic Acid (4)

Compound 1 (2-aminobutanoic acid, 5.00 g, 48.5 mmol), Boc anhydride(19.9 mL, 72.7 mmol), and NaHCO₃ (6.11 g, 72.7 mmol) were reacted usingReaction Scheme a to synthesize Compound 4,(R)/(S)-2-((tert-butoxycarbonyl)amino)butanoic acid (8.25 g, 83%) in theform of a white powder.

R_(f)=0.00 (DCM 9.5: Methanol 0.5 and few drops of acetic acid);

¹H NMR (DMSO-d₆, 300 MHz) 12.40 (C(O)OH), 7.02 (d, J=7.9 Hz, Boc-NH),3.69-3.82 (m, Chiral-H), 1.48-1.72 (m, CH₂CH₃), 1.38 (s, Boc), 0.87 (t,J=7.3 Hz, CH₂CH₃).

Preparation Example 2: Preparation of(R)/(S)-2-((tert-butoxycarbonyl)amino)pentanoic Acid (5)

Compound 2 (2-aminopentanoic acid, 10.00 g, 25.6 mmol), Boc anhydride(35.1 mL, 128.0 mmol), and NaHCO₃ (10.8 g, 128.0 mmol) were reactedusing Reaction Scheme a to synthesize Compound 5,(R)/(S)-2-((tert-butoxycarbonyl)amino)pentanoic acid (13.40 g, 83%) inthe form of a white powder.

R_(f)=0.85 (DCM 3: Methanol 17);

¹H NMR (DMSO-d₆, 400 MHz) 12.40 (C(O)OH), 7.03 (d, J=8.0 Hz, Boc-NH),3.75-3.89 (m, Chiral-H), 1.50-1.65 (m, CH₂CH₂CH₃), 1.20-1.38 (m,CH₂CH₂CH₃, Boc), 0.85 (t, J=7.4 Hz, CH₂CH₂CH₃).

Preparation Example 3: Preparation of(R)/(S)-2-((tert-butoxycarbonyl)amino)hexanoic Acid (6)

Compound 3 (2-aminohexanoic acid, 5.00 g, 38.1 mmol), Boc anhydride(15.7 mL, 57.2 mmol), and NaHCO₃ (4.80 g, 57.2 mmol) were reacted usingReaction Scheme a to synthesize Compound 6,(R)/(S)-2-((tert-butoxycarbonyl)amino)hexanoic acid (7.14 g, 81%) in theform of a white powder.

R_(f)=0.40 (DCM 9: Methanol 1);

¹H NMR (CDCl₃, 400 MHz) 10.26 (C(O)OH), 5.00 (d, J=7.6 Hz, Boc-NH),4.32-4.33 (m, Chiral-H), 1.63-1.87 (m, CH₂CH₂CH₂CH₃), 1.47 (s, Boc),1.31-1.38 (m, CH₂CH₂CH₂CH₃), 0.93 (t, J=7.0 Hz, CH₂CH₂CH₂CH₃).

Preparation Example 4: Preparation of(R)/(S)-2-((tert-butoxycarbonyl)(methyl)amino)butanoic Acid (7)

Compound 4 (3.00 g, 14.8 mmol), CH₃I (9.2 ml, 147.6 mmol), and NaH (3.54g, 147.6 mmol) were reacted using Reaction Scheme b to synthesizeCompound 7, (R)/(S)-2-((tert-butoxycarbonyl)(methyl)amino)butanoic acid(2.84 g, 88%) in the form of a yellow oil.

R_(f)=0.45 (DCM 9: Methanol 1 and few drops of acetic acid);

¹H NMR (DMSO-d₆, 300 MHz) 12.7 (C(O)OH), 4.14-4.43 (m, Chiral-H), 2.71(s, NCH₃), 1.50-1.73 (m, CH₂CH₃, Boc), 0.79-0.87 (m, CH₂CH₃).

Preparation Example 5: Preparation of(R)/(S)-2-((tert-butoxycarbonyl)(methyl)amino)pentanoic Acid (8)

Compound 5 (1.50 g, 6.90 mmol), CH₃I (4.3 ml, 69.0 mmol), and NaH (1.66g, 69.0 mmol) were reacted using Reaction Scheme b to synthesizeCompound 8, (R)/(S)-2-((tert-butoxycarbonyl)(methyl)amino)pentanoic acid(1.34 g, 83%) in the form of a yellow oil.

R_(f)=0.45 (DCM 9: Methanol 1 and few drops of acetic acid);

¹H NMR (DMSO-d₆, 300 MHz) 12.7 (C(O)OH), 4.54-4.28 (m, Chiral-H), 2.70(s, NCH₃), 1.79-1.64 (m, CH₂CH₂CH₃), 1.41-1.37 (m, CH₂CH₂CH₃, Boc),1.37-1.29 (m, CH₂CH₂CH₃).

Preparation Example 6: Preparation of(R)/(S)-2-((tert-butoxycarbonyl)(methyl)amino)hexanoic Acid (9)

Compound 6 (3.00 g, 13.0 mmol), CH₃I (8.1 ml, 129.7 mmol), and NaH (5.19g, 129.7 mmol) were reacted using Reaction Scheme b to synthesizeCompound 9, (R)/(S)-2-((tert-butoxycarbonyl)(methyl)amino)hexanoic acid(3.18 g, 100%) in the form of a yellow oil.

R_(f)=0.38 (DCM 9: Methanol 1);

¹H NMR (CDCl₃, 400 MHz) 12.6 (C(O)OH), 4.25-4.52 (m, Chiral-H), 2.70 (s,NCH₃), 1.66-1.79 (m, CH₂CH₂CH₂CH₃), 1.18-1.40 (m, CH₂CH₂CH₂CH₃, Boc),0.86-0.89 (m, CH₂CH₂CH₂CH₃).

Preparation Example 7: Preparation of tert-butyl(4-bromophenethyl)carbamate (12)

4-bromophenethylamine (3.9 ml, 25.1 mmol), K₂CO₃ (5.21 g, 37.7 mmol),and Boc anhydride (7.2 ml, 26.4 mmol) were reacted using Reaction Schemec to synthesize Compound 12, tert-butyl(4-bromophenethyl)carbamate (6.23g, 83%) in the form of a white powder.

R_(f)=0.36 (EtOAc 1: n-hexane 5);

¹H NMR (DMSO-d₆, 400 MHz) 7.46 (d, J=8.6 Hz, ArH), 7.15 (d, J=8.2 Hz,ArH), 6.87 (s, NH), 3.09-3.14 (m, NHCH₂CH₂), 2.64-2.67 (m, NHCH₂CH₂),1.35 (s, Boc).

Preparation Example 8: Preparation of3′,4′-dichloro-[1,1′-biphenyl]-4-amine hydrochloride (13)

After a compound was obtained by reacting Compound 10 (tert-butyl4-bromophenylcarbamate, 4.00 g, 14.7 mmol), 3,4-dichlorophenylboronicacid (3.37 g, 17.6 mmol), tetrakis(triphenylphosphine)palladium (0.68 g,0.59 mmol), and Na₂CO₃ (7.80 g, 73.5 mmol) using Reaction Scheme d, aBoc group was removed using 4.0 M HCl (7.9 mL, 31.5 mmol in dioxane) tosynthesize Compound 13, 3′,4′-dichloro-[1,1′-biphenyl]-4-aminehydrochloride (1.27 g, 34%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 9.94 (s, NH₃), 7.95 (d, J=2.0 Hz, ArH),7.40-7.80 (m, ArH), 7.39 (d, J=8.5 Hz, ArH).

Preparation Example 9: Preparation of4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-amine hydrochloride (14)

After a compound was obtained by reacting Compound 10 (3.99 g, 14.7mmol), 4-(trifluoromethoxy)phenylboronic acid (7.77 g, 22.0 mmol),tetrakis(triphenylphosphine)palladium (0.68 g, 0.59 mmol), and Na₂CO₃(7.77 g, 73.3 mmol) using Reaction Scheme d, a Boc group was removedusing 4.0 M HCl (12.8 mL, 51.1 mmol in dioxane) to synthesize Compound14, 4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-amine hydrochloride (1.99 g,48%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 9.45 (bRs, NH₃), 7.77 (d, J=8.7 Hz, ArH), 7.71(d, J=8.4 Hz, ArH), 7.45 (d, J=8.4 Hz, ArH), 7.28 (d, J=8.2 Hz, ArH).

Preparation Example 10: Preparation of2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methan-1-amine hydrochloride (15)

After a compound was obtained by reacting Compound 11 (tert-butyl4-bromobenzylcarbamate, 6.00 g, 21.0 mmol), 3,4-dichlorophenylboronicacid (4.80 g, 25.2 mmol), tetrakis(triphenylphosphine)palladium (0.97 g,0.84 mmol), and Na₂CO₃ (111.1 g, 104.8 mmol) using Reaction Scheme d, aBoc group was removed using 4.0 M HCl (3.1 ml, 12.3 mmol in dioxane) tosynthesize Compound 15,2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methan-1-amine hydrochloride(1.08 g, 17%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.71 (s, NH₃), 7.97 (s, ArH), 7.63-7.83 (m,ArH), 4.07 (s, NH₃CH₂).

Preparation Example 11: Preparation of(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanamine hydrochloride(16)

After a compound was obtained by reacting Compound 11 (6.00 g, 21.0mmol), 4-(trifluoromethyl)phenylboronic acid (5.97 g, 31.5 mmol),tetrakis(triphenylphosphine)palladium (0.97 g, 0.84 mmol), and Na₂CO₃(11.1 g, 104.8 mmol) using Reaction Scheme d, a Boc group was removedusing 4.0 M HCl (17.9 ml, 71.7 mmol in dioxane) to synthesize Compound16, (4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanamine hydrochloride(1.08 g, 66%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.49 (s, NH₃), 7.93 (d, J=8.2 Hz, ArH), 7.83(t, J=9.0 Hz, ArH), 7.64 (d, J=8.2 Hz, ArH), 4.09 (s, NH₃CH₂).

Preparation Example 12: Preparation of(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)methanamine hydrochloride(17)

After a compound was obtained by reacting Compound 11 (4.00 g, 14.0mmol), 4-(trifluoromethoxy)phenylboronic acid (4.32 g, 21.0 mmol),tetrakis(triphenylphosphine)palladium (0.65 g, 0.56 mmol), and Na₂CO₃(7.41 g, 69.9 mmol) using Reaction Scheme d, a Boc group was removedusing 4.0 M HCl (13.9 ml, 55.6 mmol in dioxane) to synthesize Compound17, (4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)methanaminehydrochloride (2.73 g, 65%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.33 (s, NH₃), 7.81-7.83 (m, ArH), 7.75 (d,J=8.2 Hz, ArH), 7.59 (d, J=8.2 Hz, ArH), 7.48 (d, J=8.3 Hz, ArH), 4.08(s, NH₃CH₂).

Preparation Example 13: Preparation of2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethan-1-amine hydrochloride (18)

After a compound was obtained by reacting Compound 12 (tert-butyl(4-bromophenethyl)carbamate, 1.00 g, 3.33 mmol),3,4-dichlorophenylboronic acid (0.76 g, 4.00 mmol),tetrakis(triphenylphosphine)palladium (0.15 g, 0.15 mmol), and Na₂CO₃(1.77 g, 16.7 mmol) using Reaction Scheme d, a Boc group was removedusing 4.0 M HCl (2.50 ml, 10.0 mmol in dioxane) to synthesize Compound18, 2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethan-1-amine hydrochloride(2.73 g, 65%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.33 (s, NH₃), 7.93 (d, J=1.9 Hz, ArH),7.66-7.72 (m, ArH), 7.39 (d, J=8.2 Hz, ArH), 2.98-3.07 (m, NH₃CH₂CH₂).

Preparation Example 14: Preparation of2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethan-1-amine hydrochloride(19)

After a compound was obtained by reacting Compound 12 (0.50 g, 1.67mmol), 4-(trifluoromethyl)phenylboronic acid (0.38 g, 2.00 mmol),tetrakis(triphenylphosphine)palladium (0.08 g, 0.07 mmol), and Na₂CO₃(0.88 g, 8.33 mmol) using Reaction Scheme d, a Boc group was removedusing 4.0 M HCl (1.25 ml, 5.00 mmol in dioxane) to synthesize Compound19, 2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethan-1-aminehydrochloride (0.28 g, 56%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.37 (s, NH₃), 7.71-7.91 (m, ArH), 7.44 (d,J=8.1 Hz, ArH), 3.01-3.11 (m, NH₃CH₂CH₂).

Preparation Example 15: Preparation of2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethan-1-aminehydrochloride (20)

After a compound was obtained by reacting Compound 12 (1.50 g, 5.00mmol), 4-(trifluoromethoxy)phenylboronic acid (1.23 g, 6.00 mmol),tetrakis(triphenylphosphine)palladium (0.23 g, 0.20 mmol), and Na₂CO₃(2.65 g, 25.0 mmol) using Reaction Scheme d, a Boc group was removedusing 4.0 M HCl (3.75 ml, 15.0 mmol in dioxane) to synthesize Compound20, 2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethan-1-aminehydrochloride (0.88 g, 55%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.31 (s, NH₃), 7.79 (d, J=8.7 Hz, ArH), 7.66(d, J=8.1 Hz, ArH), 7.45 (d, J=8.2 Hz, ArH), 7.40 (d, J=8.1 Hz, ArH),2.97-3.10 (m, NH₃ CH₂CH₂).

Preparation Example 16: Preparation of2-(3′,4′-difluoro-[1,1′-biphenyl]-4-yl)ethan-1-amine hydrochloride (21)

After a compound was obtained by reacting Compound 12 (1.00 g, 3.33mmol), 3,4-dichlorophenylboronic acid (0.76 g, 4.00 mmol),tetrakis(triphenylphosphine)palladium (0.15 g, 0.15 mmol), and Na₂CO₃(1.77 g, 16.7 mmol) using Reaction Scheme d, a Boc group was removedusing 4.0 M HCl (2.50 ml, 10.0 mmol in dioxane) to synthesize Compound21, 2-(3′,4′-difluoro-[1,1′-biphenyl]-4-yl)ethan-1-amine hydrochloride(2.73 g, 65%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 7.95 (s, NH₃), 7.74-7.79 (m, ArH), 7.67 (d,J=8.1 Hz, ArH), 7.48-7.54 (m, ArH), 7.37 (d, J=8.1 Hz, ArH), 2.90-3.09(m, NH₃CH₂CH₂).

Preparation Example 17: Preparation of(R)/(S)-tert-butyl(1-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)amino)-1-oxobutan-2-yl)carbamate(22)

Compound 4 (0.63 g, 3.12 mmol), NMM (0.96 ml, 8.74 mmol), IBCF (0.53 ml,4.06 mmol), and Compound 13 (0.90 g, 3.28 mmol) were reacted usingReaction Scheme e to synthesize Compound 22,(R)/(S)-tert-butyl(1-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)amino)-1-oxobutan-2-yl)carbamate(1.09 g, 82%) in the form of a pale yellow powder.

R_(f)=0.33 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 8.55 (s, C(O)NH), 7.58 (d, J=7.3 Hz, ArH),7.44-7.47 (m, ArH), 7.34 (dd, J=1.8 Hz, 8.3 Hz, ArH), 5.12 (s, Boc-NH),4.18 (s, Chiral-H), 1.67-2.05 (m, CH₂CH₃), 1.47 (s, Boc), 1.03 (t, J=7.4Hz, CH₂CH₃).

Preparation Example 18: Preparation of(R)/(S)-tert-butyl(1-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)amino)-1-oxopentan-2-yl)carbamate(23)

Compound 5 (0.30 g, 1.52 mmol), NMM (0.42 ml, 3.80 mmol), IBCF (0.26 ml,1.98 mmol), and Compound 13 (0.44 g, 1.60 mmol) were reacted usingReaction Scheme e to synthesize Compound 23,(R)/(S)-tert-butyl(1-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)amino)-1-oxopentan-2-yl)carbamate(0.61 g, 92%) in the form of a white powder.

R_(f)=0.37 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 8.53 (s, C(O)NH), 7.62 (d, J=8.6 Hz, ArH),7.48-7.50 (m, ArH), 7.38 (dd, J=2.0 Hz, 8.3 Hz, ArH), 5.08 (s, Boc-NH),4.24 (s, Chiral-H), 1.63-1.99 (m, CH₂CH₂CH₃), 1.47-1.50 (m, Boc,CH₂CH₂CH₃), 0.99 (t, J=7.3 Hz, CH₂CH₂CH₃).

Preparation Example 19: Preparation of(R)/(S)-tert-butyl(1-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)amino)-1-oxohexan-2-yl)carbamate(24)

Compound 6 (0.80 g, 3.46 mmol), NMM (0.95 ml, 8.69 mmol), IBCF (0.58 ml,4.50 mmol), and Compound 13 (1.00 g, 3.64 mmol) were reacted usingReaction Scheme e to synthesize Compound 24,(R)/(S)-tert-butyl(1-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)amino)-1-oxohexan-2-yl)carbamate(1.11 g, 71%) in the form of a white powder.

R_(f)=0.50 (EtOAc 1: n-hexane 3);

¹H NMR (DMSO-d₆, 400 MHz) 10.10 (s, NH), 7.91 (d, J=1.9 Hz, ArH),7.64-7.74 (m, ArH), 7.04 (d, J=7.8 Hz, NH), 4.02-4.07 (m, NHCHCH₂),1.57-1.64 (m, CH₂CH₂CH₂CH₃), 1.39 (s, Boc), 1.26-1.32 (m, CH₂CH₂CH₂CH₃),0.86 (t, J=6.8 Hz, CH₂CH₂CH₂CH₃).

Preparation Example 20: Preparation of(R)/(S)-tert-butyl(1-oxo-1-((4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)amino)pentan-2-yl)carbamate(25)

Compound 5 (0.43 g, 1.97 mmol), NMM (0.61 ml, 5.52 mmol), IBCF (0.33 ml,2.56 mmol), and Compound 14 (0.60 g, 2.07 mmol) were reacted usingReaction Scheme e to synthesize Compound 25,(R)/(S)-tert-butyl(1-oxo-1-((4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)amino)pentan-2-yl)carbamate(0.66 g, 73%) in the form of a white powder.

R_(f)=0.30 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 8.62 (s, C(O)NH), 7.61 (d, J=7.3 Hz, ArH), 7.54(d, J=7.6 Hz, ArH), 7.49 (d, J=7.9 Hz, ArH), 7.26-7.29 (m, ArH), 5.19(d, J=7.4 Hz, Boc-NH), 4.29 (s, Chiral-H), 1.65-1.98 (m, CH₂CH₂CH₃),1.43-1.56 (m, Boc, CH₂CH₂CH₃), 0.99 (t, J=7.1 Hz, CH₂CH₂CH₃).

Preparation Example 21: Preparation of(R)/(S)-tert-butyl(1-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)amino)-1-oxobutan-2-yl)(methyl)carbamate(26)

Compound 7 (0.68 g, 3.12 mmol), NMM (0.96 ml, 8.74 mmol), IBCF (0.53 ml,4.06 mmol), and Compound 13 (0.90 g, 3.28 mmol) were reacted usingReaction Scheme e to synthesize Compound 26,(R)/(S)-tert-butyl(1-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)amino)-1-oxobutan-2-yl)(methyl)carbamate(0.74 g, 54%) in the form of an oil.

R_(f)=0.50 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 8.50 (s, C(O)NH), 7.58-7.63 (m, ArH), 7.46-7.50(m, ArH), 7.38 (dd, J=1.8 Hz, 8.2 Hz, ArH), 4.57 (s, Chiral-H), 2.83 (s,NCH₃), 1.71-2.04 (m, CH₂CH₃), 1.51 (d, J=6.8 Hz, Boc), 0.97 (t, J=7.3Hz, CH₂CH₃).

Preparation Example 22: Preparation of(R)/(S)-tert-butyl(1-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)amino)-1-oxopentan-2-yl)(methyl)carbamate(27)

Compound 8 (0.86 g, 3.72 mmol), NMM (1.14 ml, 10.4 mmol), IBCF (0.63 ml,4.83 mmol), and Compound 13 (1.07 g, 3.90 mmol) were reacted usingReaction Scheme e to synthesize Compound 27,(R)/(S)-tert-butyl(1-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)amino)-1-oxopentan-2-yl)(methyl)carbamate(0.79 g, 47%) in the form of a yellow powder.

R_(f)=0.48 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 8.49 (s, C(O)NH), 7.58-7.64 (m, ArH), 7.47-7.51(m, ArH), 7.38 (d, J=8.3 Hz, ArH), 4.66 (s, Chiral-H), 2.82 (s, NCH₃),1.67-2.04 (m, CH₂CH₂CH₃), 1.51 (s, Boc), 1.33-1.39 (m, CH₂CH₂CH₃), 0.99(t, J=7.3 Hz, CH₂CH₂CH₃).

Preparation Example 23: Preparation of(R)/(S)-tert-butyl(1-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)amino)-1-oxohexan-2-yl)(methyl)carbamate(28)

Compound 9 (R)/(S)-2-((tert-butoxycarbonyl)(methyl)amino)hexanoic acid(0.84 g, 3.47 mmol), NMM (1.10 ml, 9.71 mmol), IBCF (0.58 ml, 4.51mmol), and Compound 13 (1.00 g, 3.64 mmol) were reacted using ReactionScheme e to synthesize Compound 28,(R)/(S)-tert-butyl(1-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)amino)-1-oxohexan-2-yl)(methyl)carbamate(0.86 g, 53%) in the form of an oil.

R_(f)=0.55 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 8.49 (s, C(O)NH), 7.58-7.64 (m, ArH), 7.47-7.51(m, ArH), 7.38 (dd, J=2.1 Hz, 8.4 Hz, ArH), 4.64 (s, Chiral-H), 2.82 (s,NCH₃), 1.67-2.01 (m, CH₂CH₂CH₂CH₃), 1.52 (s, Boc), 1.24-1.44 (m,CH₂CH₂CH₂CH₃), 0.93 (t, J=7.1 Hz, CH₂CH₂CH₃).

Preparation Example 24: Preparation of(R)/(S)-2-amino-N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)butanamidehydrochloride (29)

Compound 22 (1.06 g, 2.50 mmol) and 4.0 M HCl (3.80 ml, 15.0 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 29,(R)/(S)-2-amino-N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)butanamidehydrochloride (0.87 g, 97%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (CDCl₃, 400 MHz) 11.05 (s, C(O)NH), 8.38 (s, NH₃), 7.93 (d, J=1.9Hz, ArH), 7.66-7.79 (m, ArH), 4.01-4.04 (m, Chiral-H), 1.86-1.91 (m,CH₂CH₃), 0.96 (t, J=7.5 Hz, CH₂CH₃).

Preparation Example 25: Preparation of(R)/(S)-2-amino-N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)pentanamidehydrochloride (30)

Compound 23 (0.58 g, 1.33 mmol) and 4.0 M HCl (2.00 ml, 7.95 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 30,(R)/(S)-2-amino-N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)pentanamidehydrochloride (0.40 g, 81%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 11.05 (s, C(O)NH), 8.40 (s, NH₃), 7.93 (d,J=1.5 Hz, ArH), 7.66-7.79 (m, ArH), 4.06 (s, Chiral-H), 1.79-1.85 (m,CH₂CH₂CH₃), 1.36-1.43 (m, CH₂CH₂CH₃), 0.91 (t, J=7.3 Hz, CH₂CH₂CH₃).

Preparation Example 26: Preparation of(R)/(S)-2-amino-N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)hexanamidehydrochloride (31)

Compound 24 (1.10 g, 2.44 mmol) and 4.0 M HCl (3.66 ml, 14.6 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 31,(R)/(S)-2-amino-N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)hexanamidehydrochloride (0.81 g, 86%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 10.97 (s, C(O)NH), 8.38 (s, NH₃), 7.93 (d,J=2.0 Hz, ArH), 7.66-7.78 (m, ArH), 4.03 (s, Chiral-H), 1.81-1.87 (m,CH₂CH₂CH₂CH₃), 1.33-1.39 (m, CH₂CH₂CH₂CH₃), 0.87 (t, J=6.9 Hz,CH₂CH₂CH₂CH₃).

Preparation Example 27: Preparation of(R)/(S)-2-amino-N-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)pentanamidehydrochloride (32)

Compound 25 (0.64 g, 1.41 mmol) and 4.0 M HCl (2.12 ml, 8.46 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 32,(R)/(S)-2-amino-N-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)pentanamidehydrochloride (0.51 g, 93%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 10.90 (s, C(O)NH), 8.35 (s, NH₃), 7.76-7.79(m, ArH), 7.70 (d, J=8.8 Hz, ArH), 7.45 (d, J=8.2 Hz, ArH), 4.03 (s,Chiral-H), 1.82 (q, J=6.9 Hz, 7.9 Hz, CH₂CH₂CH₃), 1.34-1.47 (m,CH₂CH₂CH₃), 0.92 (t, J=7.3 Hz, CH₂CH₂CH₃).

Preparation Example 28: Preparation of(R)/(S)—N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(methylamino)butanamidehydrochloride (33)

Compound 26 (0.69 g, 1.58 mmol) and 4.0 M HCl (2.40 ml, 9.50 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 33,(R)/(S)—N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(methylamino)butanamidehydrochloride (0.55 g, 93%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 11.00 (s, C(O)NH), 9.13 (s, NH₂), 7.94 (d,J=1.7 Hz, ArH), 7.66-7.78 (m, ArH), 3.96 (t, J=5.5 Hz, Chiral-H), 2.57(s, NCH₃), 1.87-2.05 (m, CH₂CH₃), 0.94 (t, J=7.5 Hz, CH₂CH₃).

Preparation Example 29: Preparation of(R)/(S)—N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(methylamino)pentanamidehydrochloride (34)

Compound 27 (0.38 g, 0.83 mmol) and 4.0 M HCl (1.25 ml, 4.98 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 34,(R)/(S)—N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(methylamino)pentanamidehydrochloride (0.23 g, 71%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 10.98 (s, C(O)NH), 9.09 (s, NH₂), 7.94 (s,ArH), 7.66-7.76 (m, ArH), 3.96 (t, J=6.1 Hz, Chiral-H), 2.57 (s, NCH₃),1.80-1.93 (m, CH₂CH₂CH₃), 1.31-1.39 (m, CH₂CH₂CH₃), 0.91 (t, J=7.3 Hz,CH₂CH₂CH₃).

Preparation Example 30: Preparation of(R)/(S)—N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(methylamino)hexanamidehydrochloride (35)

Compound 28 (0.82 g, 1.77 mmol) and 4.0 M HCl (2.65 ml, 10.6 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 35,(R)/(S)—N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(methylamino)hexanamidehydrochloride (0.60 g, 84%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 10.81 (s, C(O)NH), 9.05 (s, NH₂), 7.94 (d,J=2.0 Hz, ArH), 7.66-7.77 (m, ArH), 3.92 (s, Chiral-H), 2.57 (s, NCH₃),1.87-1.99 (m, CH₂CH₂CH₂CH₃), 1.29-1.33 (m, CH₂CH₂CH₂CH₃), 0.86 (t, J=6.8Hz, CH₂CH₂CH₂CH₃).

Preparation Example 31: Preparation of(R)/(S)—N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(dimethylamino)pentanamide(36)

Compound 30 (1.0 eq), triethylamine (6.0 eq), formaldehyde (2.0 eq), anda palladium catalyst (0.4 eq) were reacted using Reaction Scheme g tosynthesize Compound 36,(R)/(S)—N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(dimethylamino)pentanamide.

¹H NMR (DMSO-d₆, 400 MHz) 10.98 (s, C(O)NH), 7.94 (s, ArH), 7.66-7.76(m, ArH), 3.96 (t, J=6.1 Hz, Chiral-H), 2.57 (s, N(CH₃)₂), 1.80-1.93 (m,CH₂CH₂CH₃), 1.31-1.39 (m, CH₂CH₂CH₃), 0.91 (t, J=7.3 Hz, CH₂CH₂CH₃).

Preparation Example 32: Preparation of (R)/(S)-tert-butyl(1-(((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)amino)-1-oxopentan-2-yl)carbamate(37)

Compound 5 (0.57 g, 2.64 mmol), NMM (0.73 ml, 6.60 mmol), IBCF (0.45 ml,3.43 mmol), and Compound 15 (0.80 g, 2.77 mmol) were reacted usingReaction Scheme e to synthesize Compound 37, (R)/(S)-tert-butyl(1-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)amino)-1-oxopentan-2-yl)carbamate(1.20 g, 100%) in the form of a white powder.

R_(f)=0.04 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 7.64 (d, J=2.0 Hz, ArH), 7.49 (dd, J=2.6 Hz, 8.5Hz, ArH), 7.33-7.40 (m, ArH), 6.48 (s, C(O)NH), 4.93 (s, Boc-NH), 4.49(d, J=4.2 Hz, NHCH₂), 4.07-4.09 (m, Chiral-H), 1.36-1.43 (m, CH₂CH₂CH₃,Boc), 0.95 (t, J=7.3 Hz, CH₂CH₂CH₃).

Preparation Example 33: Preparation of (R)/(S)-tert-butyl(1-(((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)amino)-1-oxohexan-2-yl)carbamate(38)

Compound 6 (0.38 g, 1.65 mmol), NMM (0.45 ml, 4.13 mmol), IBCF (0.28 ml,2.15 mmol), and Compound 15 (0.50 g, 1.74 mmol) were reacted usingReaction Scheme e to synthesize Compound 38, (R)/(S)-tert-butyl(1-(((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)amino)-1-oxohexan-2-yl)carbamate(0.46 g, 60%) in the form of a white powder.

R_(f)=0.19 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 7.63 (d, J=2.0 Hz, ArH), 7.49 (dd, J=4.3 Hz, 8.2Hz, ArH), 7.33-7.39 (m, ArH), 6.55 (s, C(O)NH), 4.98 (d, J=3.8 Hz,Boc-NH), 4.49 (d, J=5.5 Hz, NHCH₂), 4.07-4.11 (m, Chiral-H), 1.58-1.90(m, CH₂CH₂CH₂CH₃), 1.42 (s, Boc), 1.34 (d, J=2.2 Hz, CH₂CH₂CH₂CH₃),0.88-0.94 (m, CH₂CH₂CH₂CH₃).

Preparation Example 34: Preparation of (R)/(S)-tert-butyl(1-oxo-1(((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)amino)pentan-2-yl)carbamate(39)

Compound 5 (0.36 g, 1.66 mmol), NMM (0.46 ml, 4.14 mmol), IBCF (0.28 ml,2.15 mmol), and Compound 16 (0.50 g, 1.74 mmol) were reacted usingReaction Scheme e to synthesize Compound 39, (R)/(S)-tert-butyl(1-oxo-1-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)amino)pentan-2-yl)carbamate(0.72 g, 96%) in the form of a white powder.

R_(f)=0.17 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 300 MHz) 7.62-7.70 (m, ArH), 7.44 (dd, J=8.1 Hz, 44.7 Hz,ArH), 6.85 (s, C(O)NH), 5.16-5.18 (m, Boc-NH), 4.47-4.49 (m, ArCH₂),4.11-4.15 (m, Chiral-H), 1.54-1.89 (m, CH₂CH₂CH₃), 1.41 (s, Boc,CH₂CH₂CH₃), 0.93 (t, J=7.2 Hz, CH₂CH₂CH₃).

Preparation Example 35: Preparation of (R)/(S)-tert-butyl(1-oxo-1(((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)amino)hexan-2-yl)carbamate(40)

Compound 6 (0.54 g, 2.32 mmol), NMM (0.71 ml, 6.49 mmol), IBCF (0.39 ml,3.01 mmol), and Compound 16 (0.70 g, 2.43 mmol) were reacted usingReaction Scheme e to synthesize Compound 40, (R)/(S)-tert-butyl(1-oxo-1-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)amino)hexan-2-yl)carbamate(0.87 g, 81%) in the form of a white powder.

R_(f)=0.16 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 7.70 (q, J=4.6 Hz, 8.6 Hz, ArH), 7.57 (d, J=8.2Hz, ArH), 7.39 (d, J=8.2 Hz, ArH), 6.50 (s, C(O)NH), 4.96 (s, Boc-NH),4.53 (d, J=4.7 Hz, NHCH₂), 4.09-4.10 (m, Chiral-H), 1.59-1.94 (m,CH₂CH₂CH₂CH₃), 1.45 (s, Boc), 1.37-1.38 (m, CH₂CH₂CH₂CH₃), 0.93 (t,J=7.0 Hz, CH₂CH₂CH₂CH₃).

Preparation Example 36: Preparation of (R)/(S)-tert-butyl(1-oxo-1(((4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)methyl)amino)pentan-2-yl)carbamate(41)

Compound 5 (0.55 g, 2.51 mmol), NMM (0.77 ml, 7.02 mmol), IBCF (0.42 ml,3.26 mmol), and Compound 17 (0.80 g, 2.63 mmol) were reacted usingReaction Scheme e to synthesize Compound 41, (R)/(S)-tert-butyl(1-oxo-1(((4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)methyl)amino)pentan-2-yl)carbamate(1.05 g, 90%) in the form of a white powder.

R_(f)=0.09 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 7.57-7.61 (m, ArH), 7.53 (d, J=8.2 Hz, ArH),7.37 (d, J=8.2 Hz, ArH), 7.30 (d, J=8.2 Hz, ArH), 6.47 (s, C(O)NH), 4.96(s, Boc-NH), 4.52 (s, NHCH₂), 4.10-4.11 (m, Chiral-H), 1.59-1.94 (m,CH₂CH₂CH₃), 1.37-1.45 (m, CH₂CH₂CH₃, Boc), 0.97 (t, J=7.3 Hz,CH₂CH₂CH₃).

Preparation Example 37: Preparation of (R)/(S)-tert-butyl(1-oxo-1(((4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)methyl)amino)hexan-2-yl)carbamate(42)

Compound 6 (0.58 g, 2.51 mmol), NMM (0.77 ml, 7.02 mmol), IBCF (0.42 ml,3.26 mmol), and Compound 17 (0.80 g, 2.63 mmol) were reacted usingReaction Scheme e to synthesize Compound 42, (R)/(S)-tert-butyl(1-oxo-1(((4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)methyl)amino)hexan-2-yl)carbamate(1.06 g, 88%) in the form of a white powder.

R_(f)=0.18 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 7.58-7.61 (m, ArH), 7.53 (d, J=8.1 Hz, ArH),7.37 (d, J=8.1 Hz, ArH), 7.30 (d, J=8.5 Hz, ArH), 6.52 (s, C(O)NH), 4.99(s, Boc-NH), 4.53 (d, J=5.1 Hz, NHCH₂), 4.09-4.11 (m, Chiral-H),1.62-1.94 (m, CH₂CH₂CH₂CH₃), 1.45 (s, Boc), 1.36-1.37 (m, CH₂CH₂CH₂CH₃),0.92 (t, J=6.9 Hz, CH₂CH₂CH₂CH₃).

Preparation Example 38: Preparation of (R)/(S)-tert-butyl(1-(((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)amino)-1-oxopentan-2-yl)(methyl)carbamate(43)

Compound 8 (0.38 g, 1.65 mmol), NMM (0.46 ml, 4.13 mmol), IBCF (0.28 ml,2.15 mmol), and Compound 15 (0.50 g, 1.73 mmol) were reacted usingReaction Scheme e to synthesize Compound 43, (R)/(S)-tert-butyl(1-(((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)amino)-1-oxopentan-2-yl)(methyl)carbamate(0.57 g, 73%) in the form of an oil.

R_(f)=0.18 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 300 MHz) 7.30-7.68 (m, ArH), 6.27-6.64 (m, C(O)NH),4.41-4.59 (m, NHCH₂, Chiral-H), 2.78 (s, NCH₃), 2.04-1.63 (m,CH₂CH₂CH₃), 1.44 (s, Boc), 1.32-1.26 (m, CH₂CH₂CH₃), 0.96 (t, J=7.3 Hz,CH₂CH₂CH₃).

Preparation Example 39: Preparation of (R)/(S)-tert-butylmethyl(1-oxo-1(((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)amino)pentan-2-yl)carbamate(44)

Compound 8 (0.38 g, 1.66 mmol), NMM (0.46 ml, 4.14 mmol), IBCF (0.28 ml,2.15 mmol), and Compound 16 (0.50 g, 1.74 mmol) were reacted usingReaction Scheme e to synthesize Compound 44, (R)/(S)-tert-butyl methyl(1-oxo-1-(((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)amino)pentan-2-yl)carbamate(0.49 g, 64%) in the form of an oil.

R_(f)=0.22 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 300 MHz) 7.64-7.71 (m, ArH), 7.44 (dd, J=7.9 Hz, 53.4 Hz,ArH), 6.28-6.64 (m, C(O)NH), 4.43-4.61 (m, NHCH₂, Chiral-H), 2.78 (s,NCH₃), 1.63-2.04 (m, CH₂CH₂CH₃), 1.44 (s, Boc), 1.26-1.35 (m,CH₂CH₂CH₃), 0.96 (t, J=7.3 Hz, CH₂CH₂CH₃).

Preparation Example 40: Preparation of(R)/(S)-2-amino-N-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)pentanamidehydrochloride (45)

Compound 37 (1.19 g, 2.64 mmol) and 4.0 M HCl (3.95 ml, 15.8 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 45,(R)/(S)-2-amino-N-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)pentanamidehydrochloride (0.73 g, 71%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 300 MHz) 9.04 (s, C(O)NH), 8.21 (s, NH₃), 7.94 (s,ArH), 7.66-7.73 (m, ArH), 7.40 (d, J=8.1 Hz, ArH), 4.39-4.41 (m, NHCH₂),3.78-3.82 (t, J=6.3 Hz, Chiral-H), 1.68-1.76 (m, CH₂CH₂CH₃), 1.29-1.39(m, CH₂CH₂CH₃), 0.89 (t, J=7.2 Hz, CH₂CH₂CH₃).

Preparation Example 41: Preparation of(R)/(S)-2-amino-N-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)hexanamidehydrochloride (46)

Compound 38 (0.46 g, 0.99 mmol) and 4.0 M HCl (1.48 ml, 1.48 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 46,(R)/(S)-2-amino-N-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)hexanamidehydrochloride (0.27 g, 85%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 9.17 (m, C(O)NH), 8.32 (s, NH₃), 7.94 (d,J=2.0 Hz, ArH), 7.66-7.73 (m, ArH), 7.41 (d, J=8.2 Hz, ArH), 4.34-4.45(m, NHCH₂), 3.81 (t, J=6.1 Hz, Chiral-H), 1.75-1.76 (m, CH₂CH₂CH₂CH₃),1.27-1.28 (m, CH₂CH₂CH₂CH₃), 0.85 (t, J=6.6 Hz, CH₂CH₂CH₂CH₃).

Preparation Example 42: Preparation of(R)/(S)-2-amino-N-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)pentanamidehydrochloride (47)

Compound 39 (0.70 g, 1.55 mmol) and 4.0 M HCl (2.33 ml, 9.32 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 47,(R)/(S)-2-amino-N-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)pentanamidehydrochloride (0.60 g, 99%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 300 MHz) 9.37 (t, J=5.7 Hz, C(O)NH), 8.46 (s, NH₃),7.71-7.92 (m, ArH), 7.45-7.51 (m, ArH), 4.40-4.43 (m, NHCH₂), 3.89 (s,Chiral-H), 1.74-1.82 (m, CH₂CH₂CH₃), 1.16-1.42 (m, CH₂CH₂CH₃), 0.89 (t,J=7.2 Hz, CH₂CH₂CH₃).

Preparation Example 43: Preparation of(R)/(S)-2-amino-N-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)hexanamidehydrochloride (48)

Compound 40 (0.85 g, 1.83 mmol) and 4.0 M HCl (2.75 ml, 11.0 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 48,(R)/(S)-2-amino-N-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)hexanamidehydrochloride (0.72 g, 98%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 9.09 (s, C(O)NH), 8.23 (s, NH₃), 7.89 (d,J=8.2 Hz, ArH), 7.82 (d, J=8.4 Hz, ArH), 7.73 (d, J=8.1 Hz, ArH), 7.44(d, J=8.1 Hz, ArH), 4.36-4.46 (m, NHCH₂), 3.80 (t, J=6.4 Hz, Chiral-H),1.74-1.76 (m, CH₂CH₂CH₂CH₃), 1.27-1.29 (m, CH₂CH₂CH₂CH₃), 0.85 (t, J=6.5Hz, CH₂CH₂CH₂CH₃).

Preparation Example 44: Preparation of(R)/(S)-2-amino-N-((4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)methyl)pentanamidehydrochloride (49)

Compound 41 (1.04 g, 2.22 mmol) and 4.0 M HCl (3.34 ml, 13.3 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 49,(R)/(S)-2-amino-N-((4′-(trifluoromethoxy)[1,1′-biphenyl]-4-yl)methyl)pentanamidehydrochloride (0.82 g, 92%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 9.14 (t, J=5.7 Hz, C(O)NH), 8.30 (s, NH₃),7.77-7.81 (m, ArH), 7.67 (d, J=8.2 Hz, ArH), 7.46 (d, J=8.1 Hz, ArH),7.41 (d, J=8.2 Hz, ArH), 4.40 (d, J=5.8 Hz, NHCH₂), 3.82 (t, J=6.5 Hz,Chiral-H), 1.71-1.76 (m, CH₂CH₂CH₃), 1.28-1.38 (m, CH₂CH₂CH₃), 0.89 (t,J=7.3 Hz, CH₂CH₂CH₃).

Preparation Example 45: Preparation of(R)/(S)-2-amino-N-((4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)methyl)hexanamidehydrochloride (50)

Compound 42 (1.04 g, 2.17 mmol) and 4.0 M HCl (3.26 ml, 13.0 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 50,(R)/(S)-2-amino-N-((4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)methyl)hexanamidehydrochloride (0.88 g, 97%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 9.09 (t, J=5.8 Hz, C(O)NH), 8.25 (s, NH₃),7.78 (d, J=8.7 Hz, ArH), 7.66 (d, J=8.2 Hz, ArH), 7.45 (d, J=8.3 Hz,ArH), 7.41 (d, J=8.2 Hz, ArH), 4.35-4.44 (m, NHCH₂), 3.80 (t, J=6.4 Hz,Chiral-H), 1.72-1.75 (m, CH₂CH₂CH₂CH₃), 1.27-1.28 (m, CH₂CH₂CH₂CH₃),0.85 (t, J=6.5 Hz, CH₂CH₂CH₂CH₃).

Preparation Example 46: Preparation of(R)/(S)—N-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)-2-(methylamino)pentanamidehydrochloride (51)

Compound 43 (0.84 g, 1.81 mmol) and 4.0 M HCl (2.80 ml, 10.9 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 51,(R)/(S)—N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)-2-(methylamino)pentanamidehydrochloride (0.64 g, 88%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 300 MHz) 9.10-9.78 (m, NH₂), 9.57 (t, J=5.5 Hz,C(O)NH), 7.96 (s, ArH), 7.69-7.72 (m, ArH), 7.43 (d, J=10.7 Hz, ArH),4.42-4.44 (m, NHCH₂), 3.85-3.90 (m, Chiral-H), 2.48 (s, NCH₃), 1.76-1.90(m, CH₂CH₂CH₃), 1.26-1.38 (m, CH₂CH₂CH₃), 0.90 (t, J=7.1 Hz, CH₂CH₂CH₃).

Preparation Example 47: Preparation of(R)/(S)-2-(methylamino)-N-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)pentanamidehydrochloride (52)

Compound 44 (0.45 g, 0.97 mmol) and 4.0 M HCl (1.45 ml, 5.81 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 52,(R)/(S)-2-(methylamino)-N-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)pentanamidehydrochloride (0.32 g, 82%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 300 MHz) 9.03-9.81 (m, NH₂), 9.52 (t, J=5.5 Hz,C(O)NH), 7.72-7.92 (m, ArH), 7.46 (d, J=8.2 Hz, ArH), 4.43-4.45 (m,NHCH₂), 3.86 (s, Chiral-H), 2.48 (s, NCH₃), 1.77-1.89 (m, CH₂CH₂CH₃),1.25-1.38 (m, CH₂CH₂CH₃), 0.90 (t, J=7.2 Hz, CH₂CH₂CH₃).

Preparation Example 48: Preparation of(R)/(S)—N-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)-2-(dimethylamino)pentanamide(53)

Compound 45 (1.0 eq), triethylamine (6.0 eq), formaldehyde (1.05 eq),and a palladium catalyst (0.2 eq) were reacted using Reaction Scheme gto synthesize Compound 53,(R)/(S)—N-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)-2-(dimethylamino)pentanamide.

¹H NMR (DMSO-d₆, 300 MHz) 9.57 (t, J=5.5 Hz, C(O)NH), 7.96 (s, ArH),7.69-7.72 (m, ArH), 7.43 (d, J=10.7 Hz, ArH), 4.42-4.44 (m, NHCH₂),3.85-3.90 (m, Chiral-H), 2.48 (s, N(CH₃)₂), 1.76-1.90 (m, CH₂CH₂CH₃),1.26-1.38 (m, CH₂CH₂CH₃), 0.90 (t, J=7.1 Hz, CH₂CH₂CH₃).

Preparation Example 49: Preparation of (R)/(S)-tert-butyl(1-((2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)amino)-1-oxobutan-2-yl)carbamate(54)

Compound 4 (0.32 g, 1.57 mmol), NMM (0.43 ml, 3.93 mmol), IBCF (0.27 ml,2.05 mmol), and Compound 18 (0.50 g, 1.65 mmol) were reacted usingReaction Scheme e to synthesize Compound 54, (R)/(S)-tert-butyl(1-((2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)amino)-1-oxobutan-2-yl)carbamate(0.66 g, 93%) in the form of a white powder.

R_(f)=0.05 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 7.65 (s, ArH), 7.47-7.50 (m, ArH), 7.39 (d,J=8.2 Hz, ArH), 7.26-7.28 (m, ArH), 6.07 (s, C(O)NH), 4.94 (s, Boc-NH),3.93 (d, J=6.6 Hz, Chiral-H), 3.50-3.94 (m, NHCH₂CH₂), 2.86 (t, J=6.9Hz, NHCH₂CH₂), 1.55-2.88 (m, CH₂CH₃), 1.43 (s, Boc), 0.91 (t, J=7.4 Hz,CH₂CH₃).

Preparation Example 50: Preparation of (R)/(S)-tert-butyl(1-((2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)amino)-1-oxopentan-2-yl)carbamate(55)

Compound 5 (0.50 g, 2.30 mmol), NMM (0.51 ml, 4.60 mmol), IBCF (0.39 ml,2.99 mmol), and Compound 18 (0.73 g, 2.42 mmol) were reacted usingReaction Scheme e to synthesize Compound 55, (R)/(S)-tert-butyl(1-((2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)amino)-1-oxopentan-2-yl)carbamate(0.96 g, 89%) in the form of a white powder.

R_(f)=0.26 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 7.46-7.64 (m, ArH), 7.26-7.40 (m, ArH), 6.36 (s,C(O)NH), 5.07 (s, Boc-NH), 4.01-4.03 (m, Chiral-H), 3.47-3.61 (m,NHCH₂CH₂), 2.85 (t, J=7.0 Hz, NHCH₂CH₂), 2.67 (s, NCH₃), 1.48-1.80 (m,CH₂CH₂CH₃), 1.42 (s, Boc), 1.26-1.36 (m, CH₂CH₂CH₃), 0.90 (t, J=7.2 Hz,CH₂CH₂CH₃).

Preparation Example 51: Preparation of (R)/(S)-tert-butyl(1-((2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)amino)-1-oxohexan-2-yl)carbamate(56)

Compound 6 (0.36 g, 1.57 mmol), NMM (0.43 ml, 3.93 mmol), IBCF (0.27 g,2.05 mmol), and Compound 18 (0.50 g, 16.5 mmol) were reacted usingReaction Scheme e to synthesize Compound 56, (R)/(S)-tert-butyl(1-((2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)amino)-1-oxohexan-2-yl)carbamate(0.76 g, 100%) in the form of a white powder.

R_(f)=0.07 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 7.65 (s, ArH), 7.48 (d, J=6.3 Hz, ArH), 7.39 (d,J=8.0 Hz, ArH), 7.26-7.28 (m, ArH), 6.07 (s, C(O)NH), 4.91 (s, Boc-NH),3.97 (d, J=5.6 Hz, Chiral-H), 3.51-3.62 (m, NHCH₂CH₂), 2.86 (t, J=6.1Hz, NHCH₂CH₂), 1.51-1.81 (m, CH₂CH₂CH₂CH₃), 1.42 (s, Boc), 1.27 (d,J=6.7 Hz, CH₂CH₂CH₂CH₃), 0.87 (d, J=5.5 Hz, CH₂CH₂CH₂CH₃).

Preparation Example 52: Preparation of (R)/(S)-tert-butyl(1-oxo-1-((2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)amino)butan-2-yl)carbamate(57)

Compound 4 (0.42 g, 2.08 mmol), NMM (0.57 ml, 5.21 mmol), IBCF (0.35 ml,2.71 mmol), and Compound 19 (0.66 g, 2.19 mmol) were reacted usingReaction Scheme e to synthesize Compound 57, (R)/(S)-tert-butyl(1-oxo-1-((2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)amino)butan-2-yl)carbamate(0.92 g, 98%) in the form of a white powder.

R_(f)=0.16 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 7.70 (s, ArH), 7.57 (d, J=8.0 Hz, ArH),7.29-7.33 (m, ArH), 6.15 (s, C(O)NH), 5.00 (s, Boc-NH), 3.94-3.99 (m,Chiral-H), 3.53-3.66 (m, NHCH₂CH₂), 2.90 (t, J=7.0 Hz, NHCH₂CH₂),1.58-1.90 (m, CH₂CH₃), 1.45 (s, Boc), 0.93 (t, J=7.5 Hz, CH₂CH₃).

Preparation Example 53: Preparation of (R)/(S)-tert-butyl(1-oxo-1-((2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)amino)pentan-2-yl)carbamate(58)

Compound 5 (0.55 g, 2.53 mmol), NMM (0.69 ml, 6.31 mmol), IBCF (0.43 ml,3.28 mmol), and Compound 19 (0.80 g, 2.65 mmol) were reacted usingReaction Scheme e to synthesize Compound 58, (R)/(S)-tert-butyl(1-oxo-1-((2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)amino)pentan-2-yl)carbamate(1.05 g, 89%) in the form of a white powder.

R_(f)=0.20 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 300 MHz) 7.67 (s, ArH), 7.41 (dd, J=8.1 Hz, 63.6 Hz,ArH), 6.36 (s, C(O)NH), 5.05-5.07 (m, Boc-NH), 4.00-4.05 (m, Chiral-H),3.45-3.66 (m, NHCH₂CH₂), 2.87 (t, J=7.1 Hz, NHCH₂CH₂), 1.50-1.83 (m,CH₂CH₂CH₃), 1.42 (s, Boc), 1.28-1.39 (m, CH₂CH₂CH₃), 0.90 (t, J=7.2 Hz,CH₂CH₂CH₃).

Preparation Example 54: Preparation of (R)/(S)-tert-butyl(1-oxo-1-((2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)amino)carbamate(59)

Compound 6 (0.76 g, 3.16 mmol), NMM (0.87 ml, 7.89 mmol), IBCF (0.53 ml,4.10 mmol), and Compound 19 (1.00 g, 3.31 mmol) were reacted usingReaction Scheme e to synthesize Compound 59, (R)/(S)-tert-butyl(1-oxo-1-((2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)amino)carbamate(1.34 g, 89%) in the form of a white powder.

R_(f)=0.13 (EtOAc 1: n-hexane 3);

¹H NMR (DMSO-d₆, 400 MHz) 7.87 (d, J=8.2 Hz, ArH, C(O)NH), 7.80 (d,J=8.5 Hz, ArH), 7.66 (d, J=8.1 Hz, ArH), 7.35 (d, J=8.1 Hz, ArH), 6.73(d, J=8.2 Hz, Boc-NH), 3.83 (q, J=5.6 Hz, 8.4 Hz, Chiral-H), 3.24-3.43(m, NHCH₂CH₂), 2.77 (t, J=7.0 Hz, NHCH₂CH₂), 1.37-1.52 (m, CH₂CH₂CH₂CH₃,Boc), 1.15-1.20 (m, CH₂CH₂CH₂CH₃), 0.80 (t, J=6.8 Hz, CH₂CH₂CH₂CH₃).

Preparation Example 55: Preparation of (R)/(S)-tert-butyl(1-oxo-1-((2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)amino)butan-2-yl)carbamate(60)

Compound 4 (0.49 g, 2.40 mmol), NMM (0.66 ml, 6.00 mmol), IBCF (0.41 ml,3.12 mmol), and Compound 20 (0.80 g, 2.52 mmol) were reacted usingReaction Scheme e to synthesize Compound 60, (R)/(S)-tert-butyl(1-oxo-1-((2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)amino)butan-2-yl)carbamate(0.94 g, 84%) in the form of a white powder.

R_(f)=0.14 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 7.68-7.73 (m, ArH), 7.51-7.62 (m, ArH),7.29-7.33 (m, ArH), 6.17 (d, J=5.6 Hz, C(O)NH), 5.01 (s, NH), 3.95-3.98(m, Chiral-H), 3.51-3.67 (m, NHCH₂CH₂), 2.87-2.92 (m, NHCH₂CH₂),1.56-1.92 (m, CH₂CH₃), 1.45 (s, Boc), 0.93 (t, J=7.4 Hz, CH₂CH₃).

Preparation Example 56: Preparation of (R)/(S)-tert-butyl(1-oxo-1-((2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)amino)pentan-2-yl)carbamate(61)

Compound 5 (0.33 g, 1.50 mmol), NMM (0.41 ml, 3.75 mmol), IBCF (0.25 ml,1.95 mmol), and Compound 20 (0.50 g, 1.57 mmol) were reacted usingReaction Scheme e to synthesize Compound 61, (R)/(S)-tert-butyl(1-oxo-1-((2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)amino)pentan-2-yl)carbamate(0.70 g, 98%) in the form of a white powder.

R_(f)=0.12 (EtOAc 1: n-hexane 3);

¹H NMR (DMSO-d₆, 400 MHz) 7.88 (t, J=5.6 Hz, C(O)NH), 7.74-7.77 (m,ArH), 7.59 (d, J=8.2 Hz, ArH), 7.44 (d, J=8.1 Hz, ArH), 7.32 (d, J=8.2Hz, ArH), 6.74 (d, J=8.2 Hz, Boc-NH), 4.86 (q, J=5.6 Hz, 8.2 Hz,Chiral-H), 3.26-3.40 (m, NHCH₂CH₂), 2.76 (t, J=7.0 Hz, NHCH₂CH₂),1.37-1.52 (m, CH₂CH₂CH₃, Boc), 1.17-1.25 (m, CH₂CH₂CH₃), 0.81 (t, J=7.3Hz, CH₂CH₂CH₃).

Preparation Example 57: Preparation of (R)/(S)-tert-butyl(1-oxo-1-((2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)amino)hexan-2-yl)carbamate(62)

Compound 6 (0.50 g, 2.18 mmol), NMM (0.60 ml, 5.45 mmol), IBCF (0.37 ml,2.83 mmol), and Compound 20 (0.72 g, 2.29 mmol) were reacted usingReaction Scheme e to synthesize Compound 62, (R)/(S)-tert-butyl(1-oxo-1-((2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)amino)hexan-2-yl)carbamate(0.95 g, 88%) in the form of a white powder.

R_(f)=0.13 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 7.70-7.73 (m, ArH), 7.57 (d, J=8.1 Hz, ArH),7.32 (d, J=8.1 Hz, ArH), 6.15 (s, C(O)NH), 4.95 (s, Boc-NH), 4.00 (q,J=6.4 Hz, 7.2 Hz, Chiral-H), 3.53-3.65 (m, NHCH₂CH₂), 2.90 (t, J=7.0 Hz,NHCH₂CH₂), 1.52-1.85 (m, CH₂CH₂CH₂CH₃), 1.45 (s, Boc), 1.31-1.34 (m,CH₂CH₂CH₂CH₃), 0.90 (t, J=6.9 Hz, CH₂CH₂CH₂CH₃).

Preparation Example 58: Preparation of (R)/(S)-tert-butyl(1-((2-(3′,4′-difluoro-[1,1′-biphenyl]-4-yl)ethyl)amino)-1-oxopentan-2-yl)carbamate(63)

Compound 5 (0.50 g, 2.29 mmol), NMM (0.70 ml, 6.40 mmol), IBCF (0.39 ml,2.97 mmol), and Compound 21 (0.80 g, 2.40 mmol) were reacted usingReaction Scheme e to synthesize Compound 63, (R)/(S)-tert-butyl(1-((2-(3′,4′-difluoro-[1,1′-biphenyl]-4-yl)ethyl)amino)-1-oxopentan-2-yl)carbamate(0.97 g, 98%) in the form of a white powder.

R_(f)=0.10 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 7.46 (d, J=7.9 Hz, ArH), 7.33-7.38 (m, ArH),7.17-7.27 (m, ArH), 6.11 (s, C(O)NH), 4.92 (s, Boc-NH), 3.96-4.01 (m,Chiral-H), 3.47-3.63 (m, NHCH₂CH₂), 2.85 (t, J=7.0 Hz, NHCH₂CH₂),1.48-1.82 (m, CH₂CH₂CH₃), 1.42 (s, Boc), 1.26-1.36 (m, CH₂CH₂CH₃), 0.90(t, J=7.3 Hz, CH₂CH₂CH₃).

Preparation Example 59: Preparation of (R)/(S)-tert-butyl(1-((2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)amino)-1-oxobutan-2-yl)(methyl)carbamate(64)

Compound 7 (0.82 g, 3.78 mmol), NMM (1.04 ml, 9.44 mmol), IBCF (0.64 ml,4.91 mmol), and Compound 18 (1.20 g, 3.97 mmol) were reacted usingReaction Scheme e to synthesize Compound 64, (R)/(S)-tert-butyl(1-((2-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)amino)-1-oxobutan-2-yl)(methyl)carbamate(1.38 g, 79%) in the form of an oil.

R_(f)=0.22 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 7.66 (d, J=2.0 Hz, ArH), 7.49-7.53 (m, ArH),7.41 (dd, J=2.1 Hz, 6.3 Hz, ArH), 7.27-7.29 (m ArH), 6.26 (s, C(O)NH),4.44 (s, Chiral-H), 3.55-3.64 (m, NHCH₂CH₂), 2.87 (t, J=6.7 Hz,NHCH₂CH₂), 2.70 (s, NCH₃), 1.61-1.98 (m, CH₂CH₃), 1.45 (s, Boc), 0.88(t, J=7.4 Hz, CH₂CH₃).

Preparation Example 60: Preparation of (R)/(S)-tert-butyl(1-((2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)amino)-1-oxopentan-2-yl)(methyl)carbamate(65)

Compound 8 (0.35 g, 1.51 mmol), NMM (0.33 ml, 3.03 mmol), IBCF (0.26 ml,1.97 mmol), and Compound 18 (0.48 g, 1.59 mmol) were reacted usingReaction Scheme e to synthesize Compound 65, (R)/(S)-tert-butyl(1-((2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)amino)-1-oxopentan-2-yl)(methyl)carbamate(0.69 g, 95%) in the form of an oil.

R_(f)=0.33 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 7.46-7.64 (m, ArH), 7.35-7.40 (m, ArH),7.25-7.27 (m, ArH), 5.95-6.25 (m, C(O)NH), 4.51 (s, Chiral-H), 3.53-3.60(m, NHCH₂CH₂), 2.84 (t, J=6.6 Hz, NHCH₂CH₂), 2.67 (s, NCH₃), 1.57-1.90(m, CH₂CH₂CH₃), 1.42 (s, Boc), 1.22-1.32 (m, CH₂CH₂CH₃), 0.95 (t, J=7.3Hz, CH₂CH₂CH₃).

Preparation Example 61: Preparation of (R)/(S)-tert-butyl(1-((2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)amino)-1-oxohexan-2-yl)(methyl)carbamate(66)

Compound 9 (0.29 g, 1.20 mmol), NMM (0.33 ml, 2.99 mmol), IBCF (0.20 ml,0.16 mmol), and Compound 18 (0.38 g, 1.26 mmol) were reacted usingReaction Scheme e to synthesize Compound 66, (R)/(S)-tert-butyl(1-((2-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)amino)-1-oxohexan-2-yl)(methyl)carbamate(0.60 g, 97%) in the form of an oil.

R_(f)=0.30 (EtOAc 1: n-hexane 3);

¹H NMR (DMSO-d₆, 400 MHz) 7.89 (d, J=1.9 Hz, ArH, C(O)NH), 7.62-7.71 (m,ArH), 7.30 (d, J=8.1 Hz, ArH), 4.27-4.47 (m, Chiral-H), 3.32-3.35 (m,NHCH₂CH₂), 2.77 (t, J=6.5 Hz, NHCH₂CH₂), 2.67 (s, NCH₃), 1.53-1.71 (m,CH₂CH₂CH₂CH₃), 1.39 (s, Boc), 1.12-1.28 (m, CH₂CH₂CH₂CH₃), 0.84 (s,CH₂CH₂CH₂CH₃).

Preparation Example 62: Preparation of (R)/(S)-tert-butylmethyl(1-oxo-1((2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)amino)butan-2-yl)carbamate(67)

Compound 7 (0.62 g, 2.84 mmol), NMM (0.87 ml, 7.95 mmol), IBCF (0.48 ml,3.69 mmol), and Compound 19 (0.90 g, 2.98 mmol) were reacted usingReaction Scheme e to synthesize Compound 67, (R)/(S)-tert-butyl methyl(1-oxo-1-((2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)amino)butan-2-yl)carbamate(0.89 g, 67%) in the form of a white powder.

R_(f)=0.15 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 7.70 (t, J=9.7 Hz, ArH), 7.56 (d, J=7.9 Hz,ArH), 7.28-7.32 (m, ArH), 5.94-6.22 (m, C(O)NH), 4.45 (s, Chiral-H),3.57-3.64 (m, NHCH₂CH₂), 2.89 (d, J=6.1 Hz, NHCH₂CH₂), 2.70 (s, NCH₃),1.61-1.99 (m, CH₂CH₃), 1.45 (s, Boc), 0.89 (t, J=7.3 Hz, CH₂CH₃).

Preparation Example 63: Preparation of (R)/(S)-tert-butylmethyl(1-oxo-1((2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)amino)pentan-2-yl)carbamate(68)

Compound 8 (0.58 g, 2.53 mmol), NMM (0.69 ml, 6.31 mmol), IBCF (0.43 ml,3.28 mmol), and Compound 19 (0.80 g, 2.65 mmol) were reacted usingReaction Scheme e to synthesize Compound 68, (R)/(S)-tert-butyl methyl(1-oxo-1-((2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)amino)pentan-2-yl)carbamate(1.19 g, 98%) in the form of an oil.

R_(f)=0.26 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 300 MHz) 7.64-7.70 (m, ArH), 7.41 (dd, J=8.1 Hz, 67.4 Hz,ArH), 5.95-6.21 (s, C(O)NH), 4.52 (s, Chiral-H), 3.54-3.63 (m,NHCH₂CH₂), 2.86 (t, J=6.8 Hz, NHCH₂CH₂), 2.67 (s, NCH₃), 1.55-1.91 (m,CH₂CH₂CH₃), 1.42 (s, Boc), 1.23-1.27 (m, CH₂CH₂CH₃), 0.88-0.95 (m,CH₂CH₂CH₃).

Preparation Example 64: Preparation of (R)/(S)-tert-butylmethyl((1-oxo-1((2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)amino)hexan-2-yl)carbamate(69)

Compound 9 (0.70 g, 2.84 mmol), NMM (0.87 ml, 7.95 mmol), IBCF (0.48 ml,3.69 mmol), and Compound 19 (0.90 g, 2.98 mmol) were reacted usingReaction Scheme e to synthesize Compound 69, (R)/(S)-tert-butylmethyl(1-oxo-1-((2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)amino)hexan-2-yl)carbamate(0.88 g, 63%) in the form of a yellow powder.

R_(f)=0.32 (EtOAc 1: n-hexane 3);

¹H NMR (DMSO-d₆, 400 MHz) 7.87 (d, J=8.3 Hz, ArH, C(O)NH), 7.80 (d,J=8.4 Hz, ArH), 7.66 (d, J=8.2 Hz, ArH), 7.33 (d, J=8.1 Hz, ArH),4.27-4.47 (m, Chiral-H), 3.32-3.33 (m, NHCH₂CH₂), 2.78 (t, J=6.8 Hz,NHCH₂CH₂), 2.66 (s, NCH₃), 1.53-1.71 (m, CH₂CH₂CH₂CH₃), 1.39 (s, Boc),1.12-1.28 (m, CH₂CH₂CH₂CH₃), 0.84-0.89 (m, CH₂CH₂CH₂CH₃).

Preparation Example 65: Preparation of (R)/(S)-tert-butylmethyl(1-oxo-1((2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)amino)butan-2-yl)carbamate(70)

Compound 7 (0.65 g, 3.00 mmol), NMM (0.92 ml, 8.99 mmol), IBCF (0.51 ml,3.90 mmol), and Compound 20 (1.00 g, 3.15 mmol) were reacted usingReaction Scheme e to synthesize Compound 70, (R)/(S)-tert-butyl methyl(1-oxo-1-((2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)amino)butan-2-yl)carbamate(1.00 g, 69%) in the form of an oil.

R_(f)=0.19 (EtOAc 1: n-hexane 3);

¹H NMR (CDCl₃, 400 MHz) 7.51-7.70 (m, ArH), 7.29 (t, J=3.7 Hz, ArH),5.98-6.26 (m, C(O)NH), 4.45 (s, Chiral-H), 3.59-3.60 (m, NHCH₂CH₂), 2.87(s, NHCH₂CH₂), 2.70 (d, J=3.2 Hz, NCH₃), 1.62-2.07 (m, CH₂CH₃), 1.45 (s,Boc), 0.90 (m, CH₂CH₃).

Preparation Example 66: Preparation of (R)/(S)-tert-butylmethyl(1-oxo-1((2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)amino)pentan-2-yl)carbamate(71)

Compound 8 (0.25 g, 1.08 mmol), NMM (0.30 ml, 2.69 mmol), IBCF (0.18 ml,1.40 mmol), and Compound 20 (0.36 g, 1.13 mmol) were reacted usingReaction Scheme e to synthesize Compound 71, (R)/(S)-tert-butylmethyl(1-oxo-1-((2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)amino)pentan-2-yl)carbamate(0.32 g, 60%) in the form of a white powder.

R_(f)=0.18 (EtOAc 1: n-hexane 3);

¹H NMR (DMSO-d₆, 400 MHz) 7.89 (s, C(O)NH), 7.76 (d, J=8.4 Hz, ArH),7.59 (d, J=7.8 Hz, ArH), 7.44 (d, J=8.2 Hz, ArH), 7.30 (d, J=7.8 Hz,ArH), 4.30-4.49 (m, Chiral-H), 3.28-3.40 (m, NHCH₂CH₂), 2.77 (s,NHCH₂CH₂), 2.66 (s, NCH₃), 1.53-1.90 (m, CH₂CH₂CH₃), 1.39 (s, Boc),1.16-1.23 (m, CH₂CH₂CH₃), 0.88-0.89 (m, CH₂CH₂CH₃)

Preparation Example 67: Preparation of (R)/(S)-tert-butylmethyl(1-oxo-1((2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)amino)hexan-2-yl)carbamate(72)

Compound 9 (0.74 g, 3.00 mmol), NMM (0.92 ml, 8.99 mmol), IBCF (0.51 ml,3.90 mmol), and Compound 20 (1.00 g, 3.15 mmol) were reacted usingReaction Scheme e to synthesize Compound 72, (R)/(S)-tert-butylmethyl(1-oxo-1-((2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)amino)hexan-2-yl)carbamate(0.92 g, 60%) in the form of an oil.

R_(f)=0.29 (EtOAc 1: n-hexane 3);

¹H NMR (DMSO-d₆, 400 MHz) 7.88 (s, C(O)NH), 7.74-7.77 (m, ArH), 7.59 (d,J=8.2 Hz, ArH), 7.44 (d, J=8.0 Hz, ArH), 7.30 (d, J=8.1 Hz, ArH),4.28-4.47 (m, Chiral-H), 3.30-3.34 (m, NHCH₂CH₂), 2.77 (t, J=6.7 Hz,NHCH₂CH₂), 2.66 (s, NCH₃), 1.53-1.72 (m, CH₂CH₂CH₂CH₃), 1.39 (s, Boc),1.12-1.29 (m, CH₂CH₂CH₂CH₃), 0.84-0.90 (m, CH₂CH₂CH₂CH₃).

Preparation Example 68: Preparation of(R)/(S)-2-amino-N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)butanamidehydrochloride (73)

Compound 54 (0.66 g, 1.47 mmol) and 4.0 M HCl (2.20 ml, 8.81 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 73,(R)/(S)-2-amino-N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)butanamidehydrochloride (0.52 g, 91%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.66 (t, J=5.3 Hz, C(O)NH), 8.23 (s, NH₃),7.92 (d, J=1.9 Hz, ArH), 7.65-7.72 (m, ArH), 7.35 (d, J=8.1 Hz, ArH),3.67 (t, J=6.0 Hz, Chiral-H), 3.31-3.55 (m, NHCH₂CH₂), 2.79-2.83 (m,NHCH₂CH₂), 1.67-1.74 (m, CH₂CH₃), 0.79 (t, J=7.4 Hz, CH₂CH₃).

Preparation Example 69: Preparation of(R)/(S)-2-amino-N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)pentanamidehydrochloride (74)

Compound 55 (0.95 g, 2.04 mmol) and 4.0 M HCl (3.06 ml, 12.2 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 74,(R)/(S)-2-amino-N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)pentanamidehydrochloride (0.66 g, 80%) in the form of a yellow powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.82 (t, J=5.3 Hz, C(O)NH), 8.34 (s, NH₃),7.64-7.90 (m, ArH), 7.35-7.38 (d, J=8.1 Hz, ArH), 3.73 (t, J=6.3 Hz,Chiral-H), 3.29-3.57 (m, NHCH₂CH₂), 2.82-2.85 (m, NHCH₂CH₂), 1.60-1.67(m, CH₂CH₂CH₃), 1.14-1.22 (m, CH₂CH₂CH₃), 0.80 (t, J=7.1 Hz, CH₂CH₂CH₃).

Preparation Example 70: Preparation of(R)/(S)-2-amino-N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)hexanamidehydrochloride (75)

Compound 56 (0.75 g, 1.56 mmol) and 4.0 M HCl (2.35 ml, 9.39 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 75,(R)/(S)-2-amino-N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)hexanamidehydrochloride (0.60 g, 92%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.60 (t, J=5.5 Hz, C(O)NH), 8.18 (s, NH₃),7.91 (d, J=2.0 Hz, ArH), 7.65-7.72 (m, ArH), 7.35 (d, J=8.2 Hz, ArH),3.66 (t, J=6.2 Hz, Chiral-H), 3.28-3.58 (m, NHCH₂CH₂), 2.81-2.85 (m,NHCH₂CH₂), 1.59-1.64 (m, CH₂CH₂CH₂CH₃), 1.14-1.23 (m, CH₂CH₂CH₂CH₃),0.79 (t, J=6.8 Hz, CH₂CH₂CH₂CH₃).

Preparation Example 71: Preparation of(R)/(S)-2-amino-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)butanamidehydrochloride (76)

Compound 57 (0.90 g, 2.00 mmol) and 4.0 M HCl (3.00 ml, 12.0 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 76,(R)/(S)-2-amino-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)butanamidehydrochloride (0.75 g, 96%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.62 (s, C(O)NH), 8.17 (s, NH₃), 7.88 (d,J=8.2 Hz, ArH), 7.81 (d, J=8.4 Hz, ArH), 7.68 (d, J=8.3 Hz, ArH), 7.38(d, J=8.1 Hz, ArH), 3.66 (t, J=6.1 Hz, Chiral-H), 3.30-3.57 (m,NHCH₂CH₂), 2.82 (t, J=7.0 Hz, NHCH₂CH₂), 1.67-1.74 (m, CH₂CH₃), 0.79 (t,J=7.5 Hz, CH₂CH₃).

Preparation Example 72: Preparation of(R)/(S)-2-amino-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)pentanamidehydrochloride (77)

Compound 58 (1.03 g, 2.22 mmol) and 4.0 M HCl (5.56 ml, 22.2 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 77,(R)/(S)-2-amino-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)pentanamidehydrochloride (0.75 g, 85%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 300 MHz) 8.81 (t, J=5.3 Hz, C(O)NH), 8.35 (s, NH₃),7.84 (dd, J=8.2 Hz, 15.7 Hz, ArH), 7.54 (dd, J=8.1 Hz, 73.4 Hz, ArH),3.71-3.75 (t, J=6.3 Hz, Chiral-H), 3.30-3.60 (m, NH₂CH₂CH₂), 2.85 (t,J=6.3 Hz, NHCH₂CH₂), 1.61-1.68 (m, CH₂CH₂CH₃), 1.15-1.22 (m, CH₂CH₂CH₃),0.80 (t, J=7.2 Hz, CH₂CH₂CH₃).

Preparation Example 73: Preparation of(R)/(S)-2-amino-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)hexanamidehydrochloride (78)

Compound 59 (1.32 g, 2.76 mmol) and 4.0 M HCl (4.14 ml, 16.6 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 78,(R)/(S)-2-amino-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)hexanamidehydrochloride (0.82 g, 72%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.69 (t, J=4.9 Hz, C(O)NH), 8.26 (s, NH₃),7.88 (d, J=8.2 Hz, ArH), 7.81 (d, J=8.3 Hz, ArH), 7.68 (d, J=8.1 Hz,ArH), 7.39 (d, J=8.0 Hz, ArH), 3.69 (t, J=6.2 Hz, Chiral-H), 3.29-3.59(m, NHCH₂CH₂), 2.80-2.89 (m, NHCH₂CH₂), 1.61-1.67 (m, CH₂CH₂CH₂CH₃),1.14-1.23 (m, CH₂CH₂CH₂CH₃), 0.79 (t, J=6.8 Hz, CH₂CH₂CH₂CH₃).

Preparation Example 74: Preparation of(R)/(S)-2-amino-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)butanamidehydrochloride (79)

Compound 60 (0.91 g, 1.95 mmol) and 4.0 M HCl (2.92 ml, 11.7 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 79,(R)/(S)-2-amino-N-(2-(4′-(trifluoromethoxy)[1,1′-biphenyl]-4-yl)ethyl)butanamidehydrochloride (0.43 g, 54%) in the form of a yellow powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.67 (s, C(O)NH), 8.24 (s, NH₃), 7.35-7.89 (m,ArH), 3.67 (d, J=4.3 Hz, Chiral-H), 3.30-3.55 (m, NHCH₂CH₂), 2.80-2.85(m, NHCH₂CH₂), 1.68-1.75 (m, CH₂CH₃), 0.80 (t, J=7.5 Hz, CH₂CH₃).

Preparation Example 75: Preparation of(R)/(S)-2-amino-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)pentanamidehydrochloride (80)

Compound 61 (0.70 g, 1.45 mmol) and 4.0 M HCl (2.18 ml, 8.70 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 80,(R)/(S)-2-amino-N-(2-(4′-(trifluoromethoxy)[1,1′-biphenyl]-4-yl)ethyl)pentanamidehydrochloride (0.55 g, 91%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.71 (t, J=5.4 Hz, C(O)NH), 8.28 (s, NH₃),7.77 (d, J=8.8 Hz, ArH), 7.62 (d, J=8.2 Hz, ArH), 7.35-7.45 (m, ArH),3.70 (t, J=6.4 Hz, Chiral-H), 3.28-3.57 (m, NHCH₂CH₂), 2.80-2.86 (m,NHCH₂CH₂), 1.61-1.65 (m, CH₂CH₂CH₃), 1.13-1.24 (m, CH₂CH₂CH₃), 0.80 (t,J=7.4 Hz, CH₂CH₂CH₃).

Preparation Example 76: Preparation of(R)/(S)-2-amino-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)hexanamidehydrochloride (81)

Compound 62 (0.79 g, 1.59 mmol) and 4.0 M HCl (2.38 ml, 9.54 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 81,(R)/(S)-2-amino-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)hexanamidehydrochloride (0.62 g, 91%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.66 (t, J=5.4 Hz, C(O)NH), 8.23 (s, NH₃),7.88 (d, J=8.2 Hz, ArH), 7.81 (d, J=8.4 Hz, ArH), 7.68 (d, J=8.2 Hz,ArH), 7.39 (d, J=8.2 Hz, ArH), 3.68 (t, J=6.4 Hz, Chiral-H), 3.29-3.59(m, NHCH₂CH₂), 2.81-2.87 (m, NHCH₂CH₂), 1.60-1.66 (m, CH₂CH₂CH₂CH₃),1.13-1.23 (m, CH₂CH₂CH₂CH₃), 0.79 (t, J=7.0 Hz, CH₂CH₂CH₂CH₃).

Preparation Example 77: Preparation of(R)/(S)-2-amino-N-(2-(3′,4′-difluoro-[1,1′-biphenyl]-4-yl)ethyl)pentanamidehydrochloride (82)

Compound 62 (0.94 g, 2.17 mmol) and 4.0 M HCl (3.26 ml, 13.0 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 82,(R)/(S)-2-amino-N-(2-(3′,4′-difluoro-[1,1′-biphenyl]-4-yl)ethyl)pentanamidehydrochloride (0.68 g, 85%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.55 (s, C(O)NH), 8.10 (s, NH₃), 7.72-7.77 (m,ArH), 7.62 (d, J=8.1 Hz, ArH), 7.50-7.53 (m, ArH), 7.33 (d, J=8.1 Hz,ArH), 3.65 (t, J=5.9 Hz, Chiral-H), 3.29-3.57 (m, NHCH₂CH₂), 2.78-2.84(m, NHCH₂CH₂), 1.58 (q, J=6.9 Hz, 8.8 Hz, CH₂CH₂CH₃), 1.14-1.20 (m,CH₂CH₂CH₃), 0.80 (t, J=7.3 Hz, CH₂CH₂CH₃).

Preparation Example 78: Preparation of(R)/(S)—N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(methylamino)butanamidehydrochloride (83)

Compound 64 (1.31 g, 2.81 mmol) and 4.0 M HCl (4.20 ml, 16.9 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 83,(R)/(S)—N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(methylamino)butanamidehydrochloride (1.07 g, 94%) in the form of a yellow powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.79 (s, C(O)NH, NH₂), 7.92 (d, J=2.0 Hz,ArH), 7.65-7.72 (m, ArH), 7.36 (d, J=8.1 Hz, ArH), 3.59 (t, J=6.4 Hz,Chiral-H), 3.39-3.53 (m, NHCH₂CH₂), 2.83 (t, J=6.8 Hz, NHCH₂CH₂), 2.38(t, J=6.1 Hz, NCH₃), 1.68-1.80 (m, CH₂CH₃), 0.77 (t, J=7.5 Hz, CH₂CH₃).

Preparation Example 79: Preparation of(R)/(S)—N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(methylamino)pentanamidehydrochloride (84)

Compound 65 (0.65 g, 1.36 mmol) and 4.0 M HCl (2.03 ml, 8.13 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 84,(R)/(S)—N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(methylamino)pentanamidehydrochloride (0.33 g, 57%) in the form of a yellow powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 9.26 (s, NH₂), 8.96 (t, J=5.3 Hz, C(O)NH),7.90-7.91 (m, ArH), 7.64-7.71 (m, ArH), 7.36 (d, J=8.1 Hz, ArH),3.64-3.68 (m, Chiral-H), 3.42-3.56 (m, NHCH₂CH₂), 2.84 (t, J=6.8 Hz,NHCH₂CH₂), 2.35 (s, NCH₃), 1.60-1.77 (m, CH₂CH₂CH₃), 1.09-1.16 (m,CH₂CH₂CH₃), 0.80 (t, J=7.2 Hz, CH₂CH₂CH₃).

Preparation Example 80: Preparation of(R)/(S)—N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(methylamino)hexanamidehydrochloride (85)

Compound 66 (0.57 g, 1.16 mmol) and 4.0 M HCl (1.74 ml, 6.95 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 85,(R)/(S)—N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(methylamino)hexanamidehydrochloride (0.38 g, 75%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.70-9.36 (s, NH₂), 8.80 (t, J=5.4 Hz,C(O)NH), 7.91 (d, J=2.0 Hz, ArH), 7.65-7.72 (m, ArH), 7.35 (d, J=8.2 Hz,ArH), 3.55 (t, J=6.6 Hz, Chiral-H), 3.38-3.52 (m, NHCH₂CH₂), 2.83 (t,J=6.8 Hz, NHCH₂CH₂), 2.35 (s, NCH₃), 1.60-1.76 (m, CH₂CH₂CH₂CH₃),1.05-1.23 (m, CH₂CH₂CH₂CH₃), 0.78 (t, J=7.2 Hz, CH₂CH₂CH₂CH₃).

Preparation Example 81: Preparation of(R)/(S)-2-(methylamino)-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)butanamidehydrochloride (86)

Compound 67 (0.86 g, 1.84 mmol) and 4.0 M HCl (2.77 ml, 11.1 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 86,(R)/(S)-2-(methylamino)-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)butanamidehydrochloride (0.65 g, 88%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 9.04 (s, NH₂), 8.79 (s, C(O)NH), 7.87 (d,J=8.3 Hz, ArH), 7.80 (d, J=8.4 Hz, ArH), 7.68 (d, J=8.2 Hz, ArH), 7.39(d, J=8.2 Hz, ArH), 3.59 (t, J=2.5 Hz, 4.9 Hz, Chiral-H), 3.40-3.56 (m,NHCH₂CH₂), 2.84 (t, J=6.9 Hz, NHCH₂CH₂), 2.37 (s, NCH₃), 1.67-1.85 (m,CH₂CH₃), 0.77 (t, J=7.5 Hz, CH₂CH₃).

Preparation Example 82: Preparation of(R)/(S)-2-(methylamino)-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)pentanamidehydrochloride (87)

Compound 68 (1.17 g, 2.45 mmol) and 4.0 M HCl (3.67 ml, 14.7 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 87,(R)/(S)-2-(methylamino)-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)pentanamidehydrochloride (81%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.93-9.79 (m, NH₂), 9.04 (t, J=5.2 Hz,C(O)NH), 7.84 (dd, J=8.3 Hz, 15.1 Hz, ArH), 7.54 (dd, J=8.0 Hz, 73.4 Hz,ArH), 3.68-3.72 (m, Chiral-H), 3.42-3.58 (m, NHCH₂CH₂), 2.87 (t, J=6.7Hz, NHCH₂CH₂), 2.36 (s, NCH₃), 1.64-1.82 (m, CH₂CH₂CH₃), 1.09-1.22 (m,CH₂CH₂CH₃), 0.81 (t, J=7.1 Hz, CH₂CH₂CH₃).

Preparation Example 83: Preparation of(R)/(S)-2-(methylamino)-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)hexanamidehydrochloride (88)

Compound 69 (0.85 g, 1.72 mmol) and 4.0 M HCl (2.60 ml, 10.3 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 88,(R)/(S)-2-(methylamino)-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)hexanamidehydrochloride (0.53 g, 71%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 9.00 (s, NH₂), 8.75 (t, J=5.4 Hz, C(O)NH),7.87 (d, J=8.3 Hz, ArH), 7.81 (d, J=8.4 Hz, ArH), 7.68 (d, J=8.2 Hz,ArH), 7.38 (d, J=8.2 Hz, ArH), 3.57-3.61 (m, Chiral-H), 3.40-3.55 (m,NHCH₂CH₂), 2.84 (t, J=6.8 Hz, NHCH₂CH₂), 2.36 (s, NCH₃), 1.60-1.75 (m,CH₂CH₂CH₂CH₃), 1.06-1.24 (m, CH₂CH₂CH₂CH₃), 0.78 (t, J=7.2 Hz,CH₂CH₂CH₂CH₃).

Preparation Example 84: Preparation of(R)/(S)-2-(methylamino)-N-(2-(4′-(trifluoromethoxy)[1,1′-biphenyl]-4-yl)ethyl)butanamidehydrochloride (89)

Compound 70 (0.97 g, 2.01 mmol) and 4.0 M HCl (3.00 ml, 12.1 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 89,(R)/(S)-2-(methylamino)-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)butanamidehydrochloride (0.73 g, 88%) in the form of a yellow powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 9.00 (s, NH₂), 8.77 (s, C(O)NH), 7.77 (d,J=8.7 Hz, ArH), 7.61 (d, J=8.2 Hz, ArH), 7.44 (d, J=8.2 Hz, ArH), 7.35(d, J=8.1 Hz, ArH), 3.57-3.60 (m, Chiral-H), 3.39-3.55 (m, NHCH₂CH₂),2.82 (t, J=6.9 Hz, NHCH₂CH₂), 2.37 (s, NCH₃), 1.67-1.83 (m, CH₂CH₃),0.77 (t, J=7.5 Hz, CH₂CH₃).

Preparation Example 85: Preparation of(R)/(S)-2-(methylamino)-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)pentanamidehydrochloride (90)

Compound 71 (0.83 g, 1.67 mmol) and 4.0 M HCl (2.51 ml, 10.0 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 90,(R)/(S)-2-(methylamino)-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)pentanamidehydrochloride (0.40 g, 61%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.85-9.19 (m, NH₂), 8.75 (s, C(O)NH), 7.76 (d,J=7.7 Hz, ArH), 7.61 (d, J=7.5 Hz, ArH), 7.44 (d, J=8.0 Hz, ArH), 7.35(d, J=7.4 Hz, ArH), 3.60 (s, Chiral-H), 3.40-3.56 (m, NHCH₂CH₂), 2.83(t, J=6.5 Hz, NHCH₂CH₂), 2.36 (s, NCH₃), 1.60-1.66 (m, CH₂CH₂CH₃),1.09-1.17 (m, CH₂CH₂CH₃), 0.80 (t, J=7.0 Hz, CH₂CH₂CH₃).

Preparation Example 86: Preparation of(R)/(S)-2-(methylamino)-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)hexanamidehydrochloride (91)

Compound 72 (0.89 g, 1.74 mmol) and 4.0 M HCl (2.61 ml, 10.4 mmol indioxane) were reacted using Reaction Scheme f to synthesize Compound 91,(R)/(S)-2-(methylamino)-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)hexanamidehydrochloride (0.66 g, 86%) in the form of a white powder.

R_(f)=0.00 (EtOAc 9: acetone 1);

¹H NMR (DMSO-d₆, 400 MHz) 8.95 (s, NH₂), 8.72 (s, C(O)NH), 7.76 (d,J=8.7 Hz, ArH), 7.61 (d, J=8.1 Hz, ArH), 7.44 (d, J=8.4 Hz, ArH), 7.35(d, J=8.1 Hz, ArH), 3.57-3.60 (m, Chiral-H), 3.29-3.56 (m, NHCH₂CH₂),2.83 (t, J=6.8 Hz, NHCH₂CH₂), 2.37 (s, NCH₃), 1.59-1.74 (m,CH₂CH₂CH₂CH₃), 1.08-1.24 (m, CH₂CH₂CH₂CH₃), 0.78 (t, J=7.2 Hz,CH₂CH₂CH₂CH₃).

Preparation Example 87: Preparation of(R)/(S)—N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(dimethylamino)pentanamide(92)

Compound 74 (1.0 eq), triethylamine (6.0 eq), formaldehyde (1.05 eq),and a palladium catalyst (0.2 eq) were reacted using Reaction Scheme gto synthesize Compound 92,(R)/(S)—N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(dimethylamino)pentanamide.

¹H NMR (DMSO-d₆, 400 MHz) 8.96 (t, J=5.3 Hz, C(O)NH), 7.90-7.91 (m,ArH), 7.64-7.71 (m, ArH), 7.36 (d, J=8.1 Hz, ArH), 3.64-3.68 (m,Chiral-H), 3.42-3.56 (m, NHCH₂CH₂), 2.82-2.85 (m, NHCH₂CH₂), 2.35 (s,N(CH₃)₂), 1.60-1.77 (m, CH₂CH₂CH₃), 1.09-1.16 (m, CH₂CH₂CH₃), 0.80 (t,J=7.2 Hz, CH₂CH₂CH₃).

EXAMPLES Example 1: Analysis of Antifungal Activity Against HumanPathogenic Fungi

An in vitro antifungal susceptibility test was performed in accordancewith the US Clinical and Laboratory Standards Institute (CLSI)guidelines to measure the degree of antifungal activity of the compoundssynthesized in the Preparation Examples against opportunistic pathogenicfungi. In the present example, the minimum inhibitory concentrations(MICs) at which the compounds can inhibit the growth of fungi forpathogenic fungi Cryptococcus neoformans, Candida albicans, Candidaglabrata, and Aspergillus fumigatus were determined, and are shown inTable 1. The MIC value (μg/

) is expressed as a range value. Specifically, Candida species andCryptococcus neoformans were incubated in a Sabouraud dextrose agar(SDA) (Sigma-Aldrich) solid medium for 24 and 48 hours, respectively toobtain single colonies. The obtained single colonies were suspended in0.85% physiological saline to prepare fungal cell suspension (1 to 5×10⁶cells/

). Fungal cells 2000-fold diluted in RPMI1640 broth (Sigma-Aldrich) wereseeded on 96-well plates (5×10² to 2.5×10³ cells/

, 195

/well). Serial two-fold dilutions (128, 64, 32, 16, 8, 4, 2, 1, and 0.5μg/

) of compounds were prepared by diluting the compounds synthesizedaccording to the above preparation examples. Then, 5

from each dilution was added to the well of the 96-well plate containingfungal cell suspension to give a final suspension of 200

per well. The compound-treated Candida species and C. neoformans wereincubated at 35° C. for 48 hours and for 72 hours, respectively, andthen MICs were determined by visually observing the bottom of the96-well plate to confirm whether the fungi were developed and grown. Asa positive control, amphotericin B (AMB), which is highly toxic to thehuman body but is known as a representative antifungal agent, was used.The results are shown in Tables 1 to 3.

TABLE 1

Preparation example # MIC (μg/mL) (compound #) R1 R2 R3 X C. neoformansC. albicans C. glabrata A. fumigatus 24 (29) H H CH₃ 3,4-Cl 2~8  4~16 4~16  4~16 25 (30) H H CH₂CH₃ 3,4-Cl 2~8  4~16  4~16  4~16 26 (31) H HCH₂CH₂CH₃ 3,4-Cl 0.5~4   0.5~4   0.5~4   0.5~4   27 (32) H H CH₂CH₃4-OCF₃ 2~8  4~16  4~16  4~16 28 (33) H CH₃ CH₃ 3,4-Cl  4~16  8~32  8~32 8~32 29 (34) H CH₃ CH₂CH₃ 3,4-Cl 2~8  4~16  8~32  8~32 30 (35) H CH₃CH₂CH₂CH₃ 3,4-Cl 0.5~4   0.5~4   0.5~4   0.5~4   31 (36) CH₃ CH₃ CH₂CH₃3,4-Cl 2~8  4~16  4~16  4~16

TABLE 2

Preparation example # MIC (μg/mL) (compound #) R1 R2 R3 X C. neoformansC. albicans C. glabrata A. fumigatus 40 (45) H H CH₂CH₃ 3,4-Cl 2~8  8~32 8~32  8~32 41 (46) H H CH₂CH₂CH₃ 3,4-Cl 0.5~4   2~8 2~8 2~8 42 (47) H HCH₂CH₃ 4-CF₃  4~16  8~32  8~32  8~32 43 (48) H H CH₂CH₂CH₃ 4-CF₃  4~16 4~16  4~16  4~16 44 (49) H H CH₂CH₃ 4-OCF₃  4~16  8~32  8~32  8~32 45(50) H H CH₂CH₂CH₃ 4-OCF₃  4~16  4~16  4~16  4~16 46 (51) H CH₃ CH₂CH₃3,4-Cl 2~8  4~16  4~16  4~16 47 (52) H CH₃ CH₂CH₃ 4-CF₃  4~16  8~32 8~32  8~32 48 (53) CH₃ CH₃ CH₂CH₃ 3,4-Cl 2~8  8~32  8~32  8~32

TABLE 3

Preparation example # MIC (μg/mL) (compound #) R1 R2 R3 X C. neoformansC. albicans C. glabrata A. fumigatus 68 (73) H H CH₃ 3,4-Cl 2~8  8~32 8~32  8~32 69 (74) H H CH₂CH₃ 3,4-Cl 0.5~4   0.5~4   0.5~4   0.5~4   70(75) H H CH₂CH₂CH₃ 3,4-Cl 0.5~4   0.5~4   0.5~4   0.5~4   71 (76) H HCH₃ 4-CF₃  8~32 16~64  8~32  8~32 72 (77) H H CH₂CH₃ 4-CF₃  4~16  8~32 8~32  8~32 73 (78) H H CH₂CH₂CH₃ 4-CF₃ 2~8  4~16  4~16  4~16 74 (79) HH CH₃ 4-OCF₃  8~32  8~32  8~32  8~32 75 (80) H H CH₂CH₃ 4-OCF₃ 2~8  4~16 4~16  4~16 76 (81) H H CH₂CH₂CH₃ 4-OCF₃ 2~8 2~8 2~8 2~8 77 (82) H HCH₂CH₃ 3,4-F  4~16  4~16  4~16  4~16 78 (83) H CH₃ CH₃ 3,4-Cl 2~8  8~32 8~32  8~32 79 (84) H CH₃ CH₂CH₃ 3,4-Cl 2~8 4~1 4~1 4~1 80 (85) H CH₃CH₂CH₂CH₃ 3,4-Cl 0.5~4   0.5~4   0.5~4   0.5~4   81 (86) H CH₃ CH₃ 4-CF₃ 8~32 16~64 16~64 16~64 82 (87) H CH₃ CH₂CH₃ 4-CF₃  4~16  4~16  4~16 4~16 83 (88) H CH₃ CH₂CH₂CH₃ 4-CF₃ 2~8  4~16  4~16  4~16 84 (89) H CH₃CH₃ 4-OCF₃  8~32  8~32  8~32  8~32 85 (90) H CH₃ CH₂CH₃ 4-OCF₃  4~16 4~16  4~16  4~16 86 (91) H CH₃ CH₂CH₂CH₃ 4-OCF₃ 2~8  4~16  4~16  4~1687 (92) CH₃ CH₃ CH₃ 3,4-Cl  4~16  8~32  8~32  8~32 ABM 0.25 0.25 0.5 1

Example 2: Analysis of Antifungal Activity for Compound 74

To evaluate the antifungal activity of Compound 74, the minimuminhibitory concentration (MIC) capable of inhibiting the growth of fungiwas measured in accordance with the Clinical and Laboratory StandardsInstitute (CLSI) guidelines. Fungal cells were spread on YPD solid media(Sigma-Aldrich) and then aliquoted into the wells of the 96-well plates(2.5×10³ microconidia/ml for T. rubrum and T. mentagrophytes species orwas 2.5×10³ cfu/

for Candida albicans, Candida glabrata and Cryptococcus neoformansspecies, 195

/well). Two-fold serial dilutions of the Compound 74, of whichconcentration are ranging from 128 to 0.5 μg/ml (128, 64, 32, 16, 8, 4,2, 1 and 0.5 μg/

), ware prepared. Next, 5

from each dilution of Compound 74 was added to the well of the 96-wellplate including fungal cells to give a final suspension of 200

/well. The compound-treated fungal cells were incubated in a 35° C.incubator for 48 hours (Candida species) and for 72 hours (C. neoformansand Trichophyton species), respectively. After incubation, MICs (μg/

) were determined by visually reading the bottom of the 96-well plate todetect fungal growth. The results are shown in Table 4.

TABLE 4 Target Fungus MIC (μg/ml) T. rubrum (KCCM60443) 1~4 T. rubrum(KCCM60450) 2~4 T. mentagrophytes (KCCM60449) 2~8 C. albicans ATCC90028(WT), n = 30 2~4 C. albicans 12-99 (Mutant) 2~8 C. glabrata, n = 30 2~4C. tropicalis 2~4 C. neoformans, n = 10 2~4 A. fumigatus 2~8

Example 3: Comparison of Fast-Acting Effects of Compound 74 withCommercially Available Comparators

To evaluate fast-acting effects of Compound 74, the growth of Candidaalbicans was studied by treating Candida albicans with Compound 74 orcommercially available drug of Efinaconazole, Tavaborole, Terbinafine,or Ciclopirox at the same concentration for the same period of time.Specifically, Candida albicans were prepared at a concentration of2.5×10³ cfu/

and aliquoted at 195

/well into 96-well plates. Subsequently, Candida albicans cells in96-well plate were treated with Compound 74 or each of the commerciallyavailable comparative drugs (50 μg/

or 100 μg/

) for 30 minutes, respectively. Next, Compound 74 treated fungal cellswere seeded on YPD media (Sigma-Aldrich), and the number of singlecolonies grown was counted. The results are shown in FIG. 1. As shown inFIG. 1, it was confirmed that Compound 74 has an excellent fast-actingeffects comparing to the commercially available competitive drugs.

Example 4: Comparison of Fungicidal Effects of Compound 74 withCommercially Available Competitive Drugs

To evaluate fungicidal effects of Compound 74, the growth of T. rubrumwas studied after treating T. rubrum with Compound 74 or commerciallyavailable antifungal drug of Efinaconazole, Amorolfine, Terbinafine,Ciclopirox, or Amphotericin B (0.5, 1-, 2-, 4-, 8- or 16-fold of therespective MICs of Compound 74 or the other commercially availableantifungal drugs) for a predetermined time. Specifically, T. rubrumcells (6×10³ cfu/ml) were prepared and aliquoted at 195

/well into 96-well plates. Next, 5

of Compound 74 or each of the other commercially available drugs wasadded the well of the 96-well plate containing T. rubrum cells to give afinal suspension of 200

/well. 0, 2, 4, 6, 12, 24, 48, 72 or 120 hours after the addition,fungal cells treated with the Compound 74 or other antifungal drugs werespread on YPD solid media, and then the number of single colonies grownwas counted. The results are illustrated in FIG. 2. As shown in FIG. 2,Compound 74 exhibited fungicidal effects at the MIC concentration, whichsuggests that Compound 74 has fungicidal effects at a lowerconcentration than other comparators.

Example 5: Comparison of Biofilm Disruption Activities of Compound 74with Commercially Available Drugs

The biofilm disruption activities of Compound 74 were studied. Candidaalbicans was allowed to form a biofilm. Next, Compound 74 orcommercially available drug of Caspofungin, Amphotericin B orEfinaconazole was added to the obtained biofilm at respectiveconcentrations of 4, 8, 16 and 32 μg/

to evaluate the disruption of the biofilm. Specifically, Candidaalbicans cells (2.5×10 3 cfu/

) were seeded on a 96-well plate and incubated for 90 minutes to form abiofilm, and then the biofilm was treated with Compound 74 or each ofthe comparative drugs above, and then the growth of Candida albicans wasstudied 24 hours after the treatment. The results are presented in FIG.3. As shown in FIG. 3, it was suggested that Compound 74 of the presentinvention exhibited remarkably excellent growth inhibitory effects onCandida albicans through biofilm disruption especially in comparison tothose of the commercially available comparative drugs.

Example 6: Analysis of Antibacterial Activities

The antibacterial activities against Gram-positive bacteria,Gram-negative bacteria or multi-drug resistant bacteria were evaluatedfor the compounds of the present invention. The MIC test was conductedin accordance CLSI guidelines. E. coli(−), P. aeruginosa(−), and S.enterica(−) were used as Gram-negative bacteria, B. cereus(+), B.subtilis(+), B. coagulans(+), L. monocytogenes(+), M. luteus(+), P.acnes(+), S. epidermidis(+), and S. aureus(+) were used as Gram-positivebacteria. Methicillin-resistant Staphylococcus aureus (MRSA) was used asmulti-drug resistant bacteria. The bacterial cells were incubated untilthe OD₆₀₀ of the single colonies reached 0.1. Cells diluted in 100-foldin a MHB liquid medium (Sigma-Aldrich) were seeded on 96-well plates togive a suspension of 100

per well with 0.001 OD₆₀₀. Next, two-fold serially diluted compounds ofthe present invention (64, 32, 16, 8, 4, 2, 1, and 0.5 μg/

) were added to the wells to provide a final suspension of 200

/well. Subsequently, bacterial cells were incubated at 37° C. for 24hours, and then the MICs (μg/

) were determined by visual reading and optical density detection at 600nm (OD₆₀₀). As a positive control, Nofloxacin and Vancomycin were used.The results are shown in Tables 5 to 8.

TABLE 5 Compound B. cereus (+) B. subtilis (+) B. coagulans (+) 74 16 82 84 32 16 8 51 32 16 4 75 16 8 2, 4 46 16 8 4 85 32 16 4 30 32 16 8 7816 <4 <4 76 64 16 <4 81 16 4 <4 79 64 16 <4 31 <4 <4 <4 73 32 8 <4 86 6432 <4 89 >64 16 <4 88 >64 32 <4 91 16 16 <4 29 8 <4 <4 33 16 8 <4 35 <4<4 <4 34 8 <4 <4 Nofloxacin 1 <0.125 <0.125 Vancomycin 0.5 0.25 0.25

TABLE 6 Compound E. coli (−) S. aureus enterica (−) 74 32 >32 84 >32 >3251 >32 >32 75 32 >32 46 32 32 85 >32 >32 30 >32 >32 78 8 16 76 16 32 818 16 79 16 32 31 <4 8 73 8 16 86 32 64 89 16 32 88 8 >64 91 8 16 29 8 833 8 16 35 <4 64 34 8 32 Nofloxacin <0.125 <0.125 Vancomycin 64 >64

TABLE 7 Compound L. monocytogenes (+) M. luteus (+) P. acnes (+) 74 8 88 84 16 16 16 51 16 16 16 75 8 8 8 46 8 8 8 85 16 8 16 30 16 8, 16 16 78<4 8 >64 76 16 16 16 81 <4 <4 8 79 16 16 16 31 <4 <4 <4 73 8 8 8 86 1616 16 89 16 16 16 88 <4 >64 <4 91 <4 <4 <4 29 <4 <4 <4 33 <4 <4 <435 >64 <4 <4 34 <4 <4 <4 Nofloxacin <0.125 <0.125 <0.125 Vancomycin 0.250.25 <0.125

TABLE 8 Compound S. epidermidis (+) S. aureus (+) MRSA 74 8 8 8 84 16 1616 51 16 16 16 75 8 8 8 46 8 8 8 85 16 16 16 30 16 16 16 78 8 8 8 76 1632 32 81 8 8 8 79 8 16 16 31 <4 <4 <4 73 8 8 8 86 16 32 32 89 16 32 3288 8 8 8 91 <4 8 8 29 <4 <4 <4 33 <4 8 <4 35 <4 8 <4 34 <4 <4 <4Nofloxacin 0.5 Vancomycin 1

Example 7: Analysis of Anti-Inflammatory Activities

The anti-inflammatory effects of the compounds of the present inventionwere evaluated using RAW264.7 cells which were stimulated to secreteinterleukin 6 (IL-6). Specifically, RAW264.7 cells (obtained from KoreanCell Line Bank), mouse macrophages, were inoculated into a 12-well plateat 5×10⁵ cells/well and incubated at 37° C. for 16 to 24 hours. Thecompounds of the present invention were added to the cell culture mediumcontaining RAW264.7 cells incubated as above at a final concentration of0 or 8 μg/

, and then incubated at 37° C. for 1 hour. Next, lipopolysaccharide(LPS, Sigma-Aldrich, USA) was further added to the medium at a finalconcentration of 1 μg/

, and the medium was incubated at 37° C. for 24 hours to induce IL-6expression. Thereafter, IL-6 levels produced by the RAW264.7 cells weremeasured using an ELISA kit (Komabiotech Inc. Korea) according to themanufacturer's instructions. The results are shown in Table 9. In Table9, IL6 levels were expressed as a relative percentage (%) betweenLPS-induced IL6 levels after the treatment with the compound of thepresent invention and LPS-induced IL6 levels without the treatment ofthe compound of the present invention.

TABLE 9 Compound No. Relative IL-6 levels (%) 76 9.58 47 12 48 67 49 5050 68 52 13 32 16 53 5 77 5 45 3 80 6 82 3 83 9 36 9 87 24

INDUSTRIAL APPLICABILITY

The present invention relates to a novel compound and the use of thesame, can be used for the preparation of antifungal and antibacterialcompositions, and can be used for the development of a pharmaceuticalcomposition for preventing and treating fungal infection diseases.

1. A compound represented by the following Chemical Formula 1, astereoisomer thereof, or a pharmaceutically acceptable salt thereof:

in Formula 1, n is 0, 1, 2, 3, 4 or 5, R₁, R₂, and R₃ are eachindependently the same as or different from each other, and are eachindependently selected from hydrogen, a C₁₋₇ alkyl, a C₃₋₆ cycloalkyl,hydroxyl, a halogen, a halogenated C₁₋₇ alkyl, a C₁₋₇ alkyloxy and ahalogenated C₁₋₇ alkyloxy, and X is m substituents (m is an integer from1 to 5) which are the same as or different from each other, selectedfrom the group consisting of a halogen group, a halogenated C₁₋₇ alkylgroup and a halogenated C₁₋₇ alkoxy group.
 2. The compound, thestereoisomer thereof, or the pharmaceutically acceptable salt thereof ofclaim 1, wherein R₁ and R₂ are each independently H or methyl, ethyl,n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, cyclobutyl,n-pentyl, cyclopentyl, n-hexyl or cyclohexyl, and R₃ is methyl, ethyl,n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl ortert-butyl.
 3. The compound, the stereoisomer thereof, or thepharmaceutically acceptable salt thereof of claim 1, wherein X is anyone or two identical or different substituents selected from the groupconsisting of fluoro, chloro, trifluoromethyl and trifluoromethoxy. 4.The compound, the stereoisomer thereof, or the pharmaceuticallyacceptable salt thereof of claim 3, wherein X is p-fluoro, m-fluoro,p,m-difluoro, p-chloro, m-chloro, p,m-dichloro, p-trifluoromethyl orp-trifluoromethoxy.
 5. The compound, the stereoisomer thereof, or thepharmaceutically acceptable salt thereof of claim 1, wherein thecompound is 1)2-amino-N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)butanamide; 2)2-amino-N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)pentanamide; 3)2-amino-N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)hexanamide; 4)2-amino-N-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)pentanamide; 5)N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(methylamino)butanamide; 6)N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(methylamino)pentanamide; 7)N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(methylamino)hexanamide; 8)N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(dimethylamino)pentanamide; 9)2-amino-N-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)pentanamide; 10)2-amino-N-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)hexanamide; 11)2-amino-N-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)pentanamide;12)2-amino-N-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)hexanamide;13)2-amino-N-((4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)methyl)pentanamide;14)2-amino-N-((4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)methyl)hexanamide;15)N-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)-2-(methylamino)pentanamide;16)2-(methylamino)-N-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)pentanamide;17)N-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)-2-(dimethylamino)pentanamide;18) 2-amino-N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)butanamide;19) 2-amino-N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)pentanamide;20) 2-amino-N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)hexanamide;21)2-amino-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)butanamide;22)2-amino-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)pentanamide;23)2-amino-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)hexanamide;24)2-amino-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)butanamide;25)2-amino-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)pentanamide;26)2-amino-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)hexanamide;27) 2-amino-N-(2-(3′,4′-difluoro-[1,1′-biphenyl]-4-yl)ethyl)pentanamide;28)N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(methylamino)butanamide;29)N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(methylamino)pentanamide;30)N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(methylamino)hexanamide;31)2-(methylamino)-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)butanamide;32)2-(methylamino)-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)pentanamide;33)2-(methylamino)-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)hexanamide;34)2-(methylamino)-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)butanamide;35)2-(methylamino)-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)pentanamide;36)2-(methylamino)-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)hexanamide;or 37)N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(dimethylamino)pentanamide.6. A method for preparing the compound, the stereoisomer thereof, or thepharmaceutically acceptable salt thereof of claim 1, the methodcomprising a first step of forming a peptide bond by reacting anaminoalkanoic acid derivative compound protected by a butoxycarbonyl(Boc) protecting group, which is represented by the following Formula 2,with a biphenyl derivative compound containing a primary amine group,which is represented by the following Formula 3; and a second step ofremoving the Boc protecting group by reacting the compound obtained inthe first step with an acid:

in the formulae, n is 0, 1, 2, 3, 4 or 5, R₁, R₂ and R₃ are eachindependently the same as or different from each other, and are eachindependently selected from hydrogen, a C₁₋₇ alkyl, hydroxyl, a halogen,a halogenated C₁₋₇ alkyl, a C₁₋₇ alkyloxy and a halogenated C₁₋₇alkyloxy, and X is m substituents (m is an integer from 1 to 5) whichare the same as or different from each other, selected from the groupconsisting of a halogen group, a halogenated C₁₋₇ alkyl group and ahalogenated C₁₋₇ alkoxy group.
 7. The method of claim 6, wherein theaminoalkanoic acid derivative compound protected by the Boc protectinggroup, which is represented by Formula 2 is prepared by reacting anamino acid derivative represented by the following Formula 4 withdi-tert-butyl dicarbonate (Boc anhydride):

in the formula, R₁′, R₂ and R₃ are each independently the same as ordifferent from each other, and are each independently selected fromhydrogen, a C₁₋₇ alkyl, hydroxyl, a halogen, a halogenated C₁₋₇ alkyl, aC₁₋₇ alkyloxy and a halogenated C₁₋₇ alkyloxy.
 8. The method of claim 7,wherein when R₂ of the finally prepared compound is an alkyl, a step ofalkylating the compound by reacting the compound with a haloalkane inthe presence of a base after the above reaction is further performed. 9.The method of claim 6, wherein a biphenyl derivative compound comprisinga primary amine group, which is represented by Formula 3 is prepared byreacting a C₀₋₂ alkylamine derivative in which a halophenyl group at oneend is substituted, which is represented by the following Formula 5,with di-tert-butyl dicarbonate to introduce a Boc protecting group intoan amine group, then reacting the resulting alkylamine derivative with aphenylboronic acid derivative represented by the following Formula 6,and then reacting the reactants with an acid to remove the Bocprotecting group:

in the formulae, X′ is a halogen, and X is m substituents (m is aninteger from 1 to 5) which are the same as or different from each other,selected from the group consisting of a halogen group, a halogenatedC₁₋₇ alkyl group and a halogenated C₁₋₇ alkoxy group.
 10. The method ofclaim 9, wherein the reaction with the phenylboronic acid derivative isachieved by a cross-coupling reaction using a metal catalyst in thepresence of a base.
 11. The method of claim 6, wherein the first step isachieved by an anhydride coupling reaction performed in an organicsolvent in the presence of N-methylmorpholine (NMM) and isobutylchloroformate (IBCF).
 12. The method of claim 6, further comprising athird step of forming a secondary amine by alkylating amine after thesecond step when both R₁ and R₂ of the compound finally prepared are analkyl.
 13. An antifungal composition comprising, as an activeingredient, the compound, the stereoisomer thereof, or thepharmaceutically acceptable salt thereof of claim
 1. 14. The antifungalcomposition of claim 13, wherein the antifungal composition exhibitsantifungal activity against Cryptococcus neoformans, Candida albicans,Candida glabrata, or Aspergillus fumigatus.
 15. A pharmaceuticalcomposition for treating or preventing a fungal infectious disease,comprising, as an active ingredient, the compound, the stereoisomerthereof, or the pharmaceutically acceptable salt thereof of claim
 1. 16.The pharmaceutical composition of claim 15, wherein the fungalinfectious disease is caused by infections of Cryptococcus neoformans,Candida albicans, Candida glabrata, or Aspergillus fumigatus.
 17. Thepharmaceutical composition of claim 15, further comprising apharmaceutically acceptable carrier, diluent or excipient.
 18. Anantibacterial composition comprising, as an active ingredient, thecompound, the stereoisomer thereof, or the pharmaceutically acceptablesalt thereof of claim
 1. 19. The antibacterial composition of claim 18,wherein the antibacterial composition exhibits antibacterial activityagainst Gram-negative bacteria, Gram-positive bacteria, or multi-drugresistant bacteria.
 20. A pharmaceutical composition for treating orpreventing a bacterial infectious disease, comprising, as an activeingredient, the compound, the stereoisomer thereof, or thepharmaceutically acceptable salt thereof of claim
 1. 21. Apharmaceutical composition for treating or preventing ananti-inflammatory disease, comprising the compound, the stereoisomerthereof, or the pharmaceutically acceptable salt thereof of claim 1, anda pharmaceutically acceptable carrier, diluent or excipient.